<SEC-DOCUMENT>0001193125-25-197796.txt : 20250908
<SEC-HEADER>0001193125-25-197796.hdr.sgml : 20250908
<ACCEPTANCE-DATETIME>20250908083511
ACCESSION NUMBER:		0001193125-25-197796
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250908
DATE AS OF CHANGE:		20250908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elevance Health, Inc.
		CENTRAL INDEX KEY:			0001156039
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		EIN:				352145715
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275251
		FILM NUMBER:		251298678

	BUSINESS ADDRESS:	
		STREET 1:		220 VIRGINIA AVENUE
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46204
		BUSINESS PHONE:		8003311476

	MAIL ADDRESS:	
		STREET 1:		220 VIRGINIA AVENUE
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46204

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anthem, Inc.
		DATE OF NAME CHANGE:	20141202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WELLPOINT, INC
		DATE OF NAME CHANGE:	20100105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WELLPOINT INC
		DATE OF NAME CHANGE:	20041130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d11296d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#a9303c">This preliminary prospectus supplement relates to an effective registration statement under the
Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-275251 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#a9303c"><B>SUBJECT TO COMPLETION, DATED SEPTEMBER&nbsp;8, 2025 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated November&nbsp;1, 2023) </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g11296g00r01.jpg" ALT="LOGO" STYLE="width:2.18681in;height:0.949306in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; % Notes due 2028 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; % Notes due 2032 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; % Notes due 2036 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; % Notes due 2055 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">The
&#8195;&#8195;&#8195;% Notes due 2028, which we refer to as the 2028 notes, will mature on &#8195;&#8195;&#8195;, 2028, the &#8195;&#8195;&#8195;% Notes due 2032, which we refer to as the 2032 notes, will mature on &#8195;&#8195;&#8195;, 2032, the
&#8195;&#8195;&#8195;% Notes due 2036, which we refer to as the 2036 notes, will mature on &#8195;&#8195;&#8195;, 2036, and the&#8195;&#8195;&#8195;% Notes due 2055, which we refer to as the 2055&nbsp;notes, will mature on
&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2055. We refer to the 2028 notes, the 2032 notes, the 2036 notes and the 2055 notes collectively as the notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">We will pay interest on the 2028 notes, the 2032 notes and the 2055 notes on &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195; of each year, commencing
&#8195;&#8195;&#8195;, 2026. We will pay interest on the 2036 notes on &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195; of each year, commencing &#8195;&#8195;&#8195;, 2026. We may redeem the notes of any series at our option, in whole or in part, at
any time and from time to time, at the applicable redemption prices discussed under the caption &#8220;<I>Description of the Notes&#8212;Optional Redemption</I>.&#8221; If we experience a change of control triggering event and have not otherwise
elected to redeem the notes, we will be required to offer to repurchase the notes from holders as described under the caption &#8220;<I>Description of the Notes&#8212;Repurchase Upon a Change of Control</I>.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">The notes will be our unsecured and unsubordinated obligations and will rank equally with our other unsecured and unsubordinated indebtedness from time to
time outstanding. We do not intend to list the notes on any national securities exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Investing in the notes involves risks. See &#8220;<A HREF="#s11296_3">Risk
 Factors</A>&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Public&nbsp;Offering<BR>Price<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Underwriting</B><br><B>Discount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Proceeds,&nbsp;Before</B><br><B>Expenses,&nbsp;to</B><br><B>Elevance&nbsp;Health</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Per 2028 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">2028 notes total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Per 2032 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">2032 notes total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Per 2036 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">2036 notes total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Per 2055 note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">2055 notes total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Plus accrued interest, if any, from,&#8195;&#8195;&#8195;&#8195;2025, if settlement occurs after that date. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if
this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">The
underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository Trust Company for the accounts of its participants, including Clearstream Banking, S.A., and Euroclear Bank SA/NV, as operator of the Euroclear
System, against payment in New York, New York on or about &#8195;&#8195;&#8195;, 2025, which will be the fifth business day following the date of the pricing of the notes (such settlement being referred to as &#8220;T&#043;5&#8221;). See
&#8220;<I>Underwriting (Conflicts of Interest)&#8212;Settlement Cycle</I>.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><I>Joint Book-Running Managers </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="bottom"><B>BofA Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Deutsche&nbsp;Bank&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Mizuho</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus supplement is &#8195;&#8195;&#8195;, 2025. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#s11296_1">F<SMALL>ORWARD</SMALL>-L<SMALL>OOKING</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">S-ii</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_2">S<SMALL>UMMARY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_3">R<SMALL>ISK</SMALL> F<SMALL>ACTORS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_4">U<SMALL>SE</SMALL> <SMALL>OF</SMALL>
P<SMALL>ROCEEDS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_5">S<SMALL>ELECTED</SMALL> C<SMALL>ONSOLIDATED</SMALL> H<SMALL>ISTORICAL</SMALL> F<SMALL>INANCIAL
</SMALL> D<SMALL>ATA</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_6">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> N<SMALL>OTES</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_7">M<SMALL>ATERIAL</SMALL> U<SMALL>NITED</SMALL> S<SMALL>TATES</SMALL> F<SMALL>EDERAL
</SMALL> I<SMALL>NCOME</SMALL> T<SMALL>AX</SMALL> C<SMALL>ONSIDERATIONS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_8">U<SMALL>NDERWRITING</SMALL> (C<SMALL>ONFLICTS</SMALL> <SMALL>OF</SMALL> I<SMALL>NTEREST
</SMALL>)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_9">L<SMALL>EGAL</SMALL> M<SMALL>ATTERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_10">E<SMALL>XPERTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_11">W<SMALL>HERE</SMALL> Y<SMALL>OU</SMALL> C<SMALL>AN</SMALL> F<SMALL>IND</SMALL> M<SMALL>ORE
</SMALL> I<SMALL>NFORMATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#s11296_12">I<SMALL>NCORPORATION</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> D<SMALL>OCUMENTS
</SMALL> <SMALL>BY</SMALL> R<SMALL>EFERENCE</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_20">A<SMALL>BOUT</SMALL> T<SMALL>HIS</SMALL>
P<SMALL>ROSPECTUS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_21">C<SMALL>AUTIONARY</SMALL> N<SMALL>OTE</SMALL> R<SMALL>EGARDING</SMALL> F<SMALL>ORWARD
</SMALL><FONT STYLE="white-space:nowrap">-L</FONT><SMALL>OOKING</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_22">W<SMALL>HERE</SMALL> Y<SMALL>OU</SMALL> C<SMALL>AN</SMALL> F<SMALL>IND</SMALL> M<SMALL>ORE
</SMALL> I<SMALL>NFORMATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_23">I<SMALL>NCORPORATION</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> D<SMALL>OCUMENTS
</SMALL> <SMALL>BY</SMALL> R<SMALL>EFERENCE</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_24">O<SMALL>UR</SMALL> C<SMALL>OMPANY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_25">R<SMALL>ISK</SMALL> F<SMALL>ACTORS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_26">U<SMALL>SE</SMALL> <SMALL>OF</SMALL>
P<SMALL>ROCEEDS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_27">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> D<SMALL>EBT
</SMALL> S<SMALL>ECURITIES</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_28">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> P<SMALL>REFERRED
</SMALL> S<SMALL>TOCK</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_29">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> C<SMALL>OMMON
</SMALL> S<SMALL>TOCK</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_30">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> D<SMALL>EPOSITARY
</SMALL> S<SMALL>HARES</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_31">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> W<SMALL>ARRANTS
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_32">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> R<SMALL>IGHTS
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_33">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> S<SMALL>TOCK
</SMALL> P<SMALL>URCHASE</SMALL> C<SMALL>ONTRACTS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> U<SMALL>NITS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_34">P<SMALL>LAN</SMALL> <SMALL>OF</SMALL>
D<SMALL>ISTRIBUTION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_35">V<SMALL>ALIDITY</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> S<SMALL>ECURITIES
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_36">E<SMALL>XPERTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Elevance
Health&#8221; refer to Elevance Health, Inc. or Elevance Health, Inc. and its direct and indirect subsidiaries, as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement,
the accompanying prospectus or in any free writing prospectus filed by us with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). We take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We are not, and the underwriters are not, making an offer to sell the notes in any jurisdiction where the offer and sale is not permitted. You should not assume that the information contained in this prospectus
supplement, the accompanying prospectus, any free writing prospectus or any document incorporated by reference is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may
have changed since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_1"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, contain
certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words
such as &#8220;expect,&#8221; &#8220;feel,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221;
&#8220;forecast,&#8221; &#8220;plan&#8221; and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the SEC from time to time, which attempt to advise
interested parties of the factors that affect our business, including &#8220;Risk Factors&#8221; set forth in Item 1A of Part I of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024.
Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare
costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or
changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact
of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and
modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and
market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks
and uncertainties regarding Medicare and Medicaid programs, including those related to <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers
for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with
litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including
medical malpractice or professional liability claims and <FONT STYLE="white-space:nowrap">non-compliance</FONT> by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity
related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not
adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay
dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market
volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to
attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary may not contain all of the information that may be important to you. You should read the entire prospectus supplement
and the accompanying prospectus, as well as the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, before making an investment decision. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elevance
Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 45.6&nbsp;million medical members through our
affiliated health plans as of June&nbsp;30, 2025. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services
to <FONT STYLE="white-space:nowrap">fee-based</FONT> customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services.
We provide services to the federal government in connection with our Federal Health Products&nbsp;&amp; Services business, which administers the Federal Employees Program<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. We provide an array
of specialty services both to customers of our subsidiary health plans and to unaffiliated health plans, including pharmacy services, stop loss insurance, dental, vision and supplemental health insurance benefits, as well as integrated health
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an independent licensee of the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30
counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these
service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states
as Wellpoint, Carelon, MMM and/or Simply Healthcare. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our portfolio consists of the following core <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT>
brands: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield&#8212;represents our Anthem-branded and affiliated Blue Cross
and/or Blue Shield licensed Medicare, Medicaid, and commercial Health Benefit plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wellpoint&#8212;represents our Wellpoint branded Medicare, Medicaid and commercial Health Benefit plans and other
<FONT STYLE="white-space:nowrap">non-BCBSA</FONT> brands; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Carelon&#8212;represents our healthcare related services and capabilities, including our CarelonRx and Carelon
Services businesses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We report our results of operations in the following four reportable segments: Health Benefits,
CarelonRx, Carelon Services and Corporate&nbsp;&amp; Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elevance Health is incorporated under the laws of the State of Indiana. Our principal executive offices are located at 220 Virginia Avenue,
Indianapolis, Indiana 46204 and our telephone number is (833) <FONT STYLE="white-space:nowrap">401-1577.</FONT> We </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintain a website at <I>www.elevancehealth.com</I> where general information about us is available. We are not incorporating the contents of the website into this prospectus supplement or the
accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to find more information about us, please see the sections entitled &#8220;<I>Where You Can
Find More Information</I>&#8221; and &#8220;<I>Incorporation of Certain Documents by Reference</I>&#8221; in this prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuer</B>&#8201; </P></TD>
<TD>Elevance Health, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Securities Offered</B> </P></TD>
<TD>$&#8195;&#8195;&#8195; aggregate principal amount of &#8195;&#8195;% notes due 2028. </TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$&#8195;&#8195;&#8195; aggregate principal amount of &#8195;&#8195;% notes due 2032. </TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$&#8195;&#8195;&#8195; aggregate principal amount of &#8195;&#8195;% notes due 2036. </TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$&#8195;&#8195;&#8195; aggregate principal amount of &#8195;&#8195;% notes due 2055. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Maturity Dates</B> </P></TD>
<TD>For the 2028 notes, &#8195;&#8195;&#8195;, 2028. </TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the 2032 notes, &#8195;&#8195;&#8195;, 2032. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the 2036 notes, &#8195;&#8195;&#8195;, 2036. </TD></TR></TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the 2055 notes, &#8195;&#8195;&#8195;, 2055. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates</B> </P></TD>
<TD>For the 2028 notes, the 2032 notes and the 2055 notes, &#8195;&#8195; and &#8195;&#8195;, commencing &#8195;&#8195;, 2026. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the 2036 notes, &#8195;&#8195; and &#8195;&#8195;, commencing &#8195;&#8195;, 2026. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption</B>&#8201; </P></TD>
<TD>Prior to (i)&nbsp;with respect to the 2028 notes, &#8195;&#8195;, 2028 (one month prior to the maturity date of such notes), (ii) with respect to the 2032 notes, &#8195;&#8195;, 2032 (two months prior to the maturity date of such notes), (iii)
with respect to the 2036 notes, &#8195;&#8195;, 2035 (three months prior to the maturity date of such notes), and (iv) with respect to the 2055 notes, &#8195;&#8195;, 2055 (six months prior to the maturity date of such notes) (each such date, a
&#8220;Par Call Date&#8221;), we may redeem the applicable series of notes at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal
places) equal to the greater of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="43%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(1) (a) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed discounted to the redemption date (assuming such notes matured on their applicable Par Call
Date) on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months) at the Treasury Rate (as defined below) plus &#8195;&#8195; basis points in the
case of the 2028 notes, &#8195;&#8195; basis points in the case of the 2032 notes,&#8195;&#8195; basis points in the case of the 2036 notes, and &#8195;&#8195; basis points in the case of the 2055 notes, less (b)&nbsp;interest accrued to the
redemption date; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="43%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(2) 100% of the principal amount of the notes to be redeemed, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plus, in either case, accrued and unpaid interest on the applicable notes to the redemption date. See &#8220;<I>Description of the Notes&#8212; Optional Redemption</I>.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On or after the applicable Par Call Date for the respective notes, we may redeem the notes of the applicable series in whole
or in part, at any time and from time to time, at a redemption price equal to 100% </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon to such redemption date. See &#8220;<I>Description of the Notes&#8212;Optional Redemption</I>.&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Repurchase Upon Change of Control</B>&#8201; </P></TD>
<TD>Unless we have exercised our right to redeem the notes in full, upon the occurrence of both (i)&nbsp;a change of control of us and (ii)&nbsp;a downgrade of a series of notes below an investment grade rating by each of Moody&#8217;s Ratings,
S&amp;P Global Ratings and Fitch Ratings, Inc. within a specified period, we will be required to make an offer to purchase all of the notes of such series at a price in cash equal to 101% of the principal amount of the notes, plus any accrued and
unpaid interest to the date of repurchase. See &#8220;<I>Description of the Notes&#8212;Repurchase Upon a Change of Control</I>.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ranking</B> </P></TD>
<TD>The notes will be our unsecured and unsubordinated obligations and will rank equally with all of our current and future unsecured and unsubordinated indebtedness, including any borrowings under our senior credit facility, and senior to all of
our future subordinated debt. The notes will effectively rank junior to any of our future secured indebtedness to the extent of the value of the assets securing such indebtedness. The notes will not be guaranteed by any of our subsidiaries and will
therefore be effectively subordinated to all existing and future liabilities of our subsidiaries. The indenture does not restrict our ability or the ability of our subsidiaries to incur other indebtedness. As of June&nbsp;30, 2025, we had
approximately $30.2&nbsp;billion of indebtedness outstanding, of which approximately $0.4&nbsp;billion consisted of indebtedness of our subsidiaries and approximately $0.4&nbsp;billion was secured debt. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Sinking Fund</B> </P></TD>
<TD>None. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Form and Denomination of Notes</B>&#8201; </P></TD>
<TD>The notes of each series will initially be represented by one or more global notes which will be deposited with a custodian for, and registered in the name of a nominee of, The Depository Trust Company (&#8220;DTC&#8221;). Indirect holders
trading their beneficial interests in the global notes through DTC must trade in DTC&#8217;s <FONT STYLE="white-space:nowrap">same-day</FONT> funds settlement system and pay in immediately available funds. The notes may only be withdrawn from DTC in
the limited situations described in the accompanying prospectus under the caption &#8220;<I>Description of the Debt Securities&#8212;Global Notes, Delivery and Form</I>.&#8221; The notes of each series will be issued in minimum denominations of
$1,000 or an integral multiple thereof. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds of this offering, after deducting the underwriting discount and estimated offering expenses payable by us, will be
approximately $&#8195;&#8195;. We intend to use the net proceeds of this offering to repay or redeem all of the $400&nbsp;million aggregate principal amount of our 5.350% senior notes due 2025 (the &#8220;2025 Notes&#8221;) and to redeem or
otherwise repurchase all of the $500&nbsp;million </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
aggregate principal amount of our 4.900% senior notes due 2026 (the &#8220;2026 Notes&#8221;), in each case at or prior to their respective maturities. We intend to use the remainder of the net
proceeds from this offering for working capital and for general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of other short-term and long-term debt, and the repurchase of our common stock pursuant to our
share repurchase program. See &#8220;<I>Use of Proceeds</I>.&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest</B> </P></TD>
<TD>Certain of the underwriters and/or their respective affiliates and associated persons may own a portion of the 2025 Notes and/or the 2026 Notes. If any of the underwriters, together with their respective affiliates and associated persons,
receive at least 5% of the net proceeds from this offering, not including underwriting compensation, as a result of our intended use of the net proceeds from the sale of the notes, such underwriters will be deemed to have a &#8220;conflict of
interest&#8221; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA Rule 5121&#8221;). However, pursuant to FINRA Rule 5121, the appointment of a qualified independent underwriter is not necessary in
connection with this offering because the notes are &#8220;investment grade rated&#8221; as defined by FINRA Rule 5121. See &#8220;<I>Underwriting (Conflicts of Interest)&#8212;Conflicts of Interest</I>.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Further Issues</B>&#8201; </P></TD>
<TD>We may from time to time, without the consent of the holders of the notes, create and issue additional notes having substantially the same terms and conditions, other than the issue date, the offering price, and, if applicable, the original
interest accrual date and/or the initial interest payment date, as the 2028 notes, the 2032 notes, the 2036 notes, or the 2055 notes, in each case, so that such issue shall be consolidated and form a single series with the outstanding 2028 notes,
2032 notes, 2036 notes, or 2055 notes offered hereby; provided that if such additional notes are not fungible with such notes for U.S. federal income tax purposes, the additional notes will have a separate CUSIP number. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Trustee, Registrar and Paying Agent</B> </P></TD>
<TD>The Bank of New York Mellon Trust Company, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>See &#8220;Risk Factors&#8221; before considering an investment in any of the notes. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In considering whether to invest in any of the notes, you should carefully consider all of the information contained in or incorporated by
reference in this prospectus supplement and the accompanying prospectus. In particular, you should consider the risk factors described in our periodic reports filed with the SEC, including those set forth under the caption &#8220;Risk Factors&#8221;
in Item&nbsp;1A of Part&nbsp;I of our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2024, which are incorporated by reference in this prospectus supplement, as well as the additional
risks described below. If any of the risks actually occur, our business, financial condition or results of operations could suffer. In that event, we may be unable to meet our obligations under the notes and you may lose all or part of your
investment. Additional risks and uncertainties not currently known to us or those currently viewed by us to be immaterial may also materially and adversely affect us. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As of June&nbsp;30,
2025, we had indebtedness outstanding of approximately $30.2&nbsp;billion and expect to incur additional indebtedness in the future. As a holding company, we will not be able to repay our indebtedness except through dividends from subsidiaries, some
of which are restricted in their ability to pay such dividends under applicable insurance law and undertakings. Such indebtedness could also adversely affect our ability to pursue desirable business opportunities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, we had indebtedness outstanding of approximately $30.2&nbsp;billion and had available borrowing capacity of
$4.0&nbsp;billion under our <FONT STYLE="white-space:nowrap">5-year</FONT> senior revolving credit facility. On September&nbsp;5, 2025, we amended and restated&nbsp;the credit agreement for our <FONT STYLE="white-space:nowrap">5-year</FONT> senior
revolving credit facility to, among other things, extend the maturity date from April 2027 to September 2030, and increase the amount of credit available from $4.0&nbsp;billion to $5.0&nbsp;billion. We expect to incur additional indebtedness in the
future. The terms of the indenture under which the notes are issued do not prohibit us or our subsidiaries from incurring additional indebtedness. Our debt service obligations will require us to use a portion of our cash flow to pay interest and
principal on debt instead of for other corporate purposes, including funding future expansion. If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends from our
subsidiaries, sell assets, seek additional equity or debt capital or restructure our debt. However, these measures might be unsuccessful or inadequate in permitting us to meet scheduled debt service obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holding company, we have no operations and are dependent on dividends from our subsidiaries for cash to fund our debt service and other
corporate needs. Our subsidiaries are separate legal entities. Furthermore, our subsidiaries are not obligated to make funds available to us, and creditors of our subsidiaries will have a superior claim to certain of our subsidiaries&#8217; assets.
State insurance laws restrict the ability of our regulated subsidiaries to pay dividends, and in some states we have made special undertakings that may limit the ability of our regulated subsidiaries to pay dividends. In addition, our
subsidiaries&#8217; ability to make any payments to us will also depend on their earnings, the terms of their indebtedness, business and tax considerations and other legal restrictions. We cannot assure you that our subsidiaries will be able to pay
dividends or otherwise contribute or distribute funds to us in an amount sufficient to pay the principal of or interest on the indebtedness owed by us. Indebtedness could also limit our ability to pursue desirable business opportunities, and may
affect our ability to maintain an investment grade rating for our indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also incur future debt obligations that might
subject us to restrictive covenants that could affect our financial and operational flexibility. Our breach or failure to comply with any of these covenants could result in a default under our credit agreement. If we default under our credit
agreement, the lenders could cease to make further extensions of credit or cause all of our outstanding debt obligations under our credit agreement to become immediately due and payable, together with accrued and unpaid interest. If the indebtedness
under the notes or our credit agreement is accelerated, we may be unable to repay or finance the amounts due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The notes are not secured by any of our assets and any secured creditors would have a prior claim on
our assets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are not secured by any of our assets. The terms of the indenture permit us to incur secured debt. If we
become insolvent or are liquidated, or if payment under any agreements governing our secured debt is accelerated, the lenders under any secured debt agreements would be entitled to exercise the remedies available to a secured lender under applicable
law and pursuant to agreements governing that debt. Accordingly, the lenders would have a prior claim on our assets. In that event, because the notes are not secured by any of our assets, it is possible that there would be no assets remaining from
which claims of the holders of the notes could be satisfied or, if any assets remain, the remaining assets might be insufficient to satisfy those claims in full. As of June&nbsp;30, 2025, we had approximately $0.4&nbsp;billion of secured debt
outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The notes are effectively subordinated to the indebtedness of our subsidiaries. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we operate as a holding company, our right to participate in any distribution of assets of any subsidiary upon that subsidiary&#8217;s
dissolution, <FONT STYLE="white-space:nowrap">winding-up,</FONT> liquidation, reorganization or otherwise (and thus the ability of the holders of the notes to participate indirectly from the distribution) is subject to the prior claims of the
creditors of that subsidiary, except to the extent that we are a creditor of the subsidiary and our claims are recognized. Therefore, the notes are effectively subordinated to all indebtedness and other obligations of our subsidiaries. Our
subsidiaries are separate legal entities and have no obligations to pay, or make funds available for the payment of, any amounts due on the notes. The indenture governing the notes does not prohibit or limit the incurrence of indebtedness and other
liabilities by us or our subsidiaries. The incurrence of additional indebtedness and other liabilities by us or our subsidiaries could adversely affect our ability to pay obligations on the notes. As of June&nbsp;30, 2025, we had approximately
$30.2&nbsp;billion of indebtedness outstanding, of which approximately $0.4&nbsp;billion consisted of indebtedness of our subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not
be able to satisfy our obligations to repurchase the notes upon the occurrence of both a change of control and downgrades of the notes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we have exercised our right to redeem the notes in full, upon the occurrence of both (1)&nbsp;a change of control of us and (2)&nbsp;a
downgrade of a series of notes below an investment grade rating by each of Moody&#8217;s Ratings, S&amp;P Global Ratings and Fitch Ratings, Inc. within a specified period, which we refer to as a change of control triggering event, we will be
required to make an offer to purchase all of the notes of such series at a price in cash equal to 101% of the principal amount of the notes, plus any accrued and unpaid interest to the date of repurchase. The source of funds for any purchase of our
debt securities, including the notes, will be our available cash or cash generated from our operations or other sources, including borrowings, sales of assets or sales of equity. We may not be able to repurchase the notes upon a change of control
triggering event because we may not have sufficient financial resources to purchase all of the debt securities that are tendered upon a change of control and repay our other indebtedness that will become due, if any. We may require additional
financing from third parties to fund any such purchases, and we cannot assure you that we would be able to obtain financing on satisfactory terms or at all. Further, our ability to repurchase the notes may be limited by applicable law. See
&#8220;<I>Description of the Notes&#8212;Repurchase Upon a Change of Control.</I>&#8221; As a result of our potential obligations to repurchase the notes and other indebtedness, we may have to avoid certain change of control transactions that would
otherwise be beneficial to us and our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are currently no trading markets for the notes, and active public trading markets for the
notes may not develop or, if any markets develop, may not be maintained. The failure of active liquid trading markets for the notes to develop or be maintained is likely to adversely affect the market prices and liquidity of the notes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are new issues of securities, and there are currently no existing trading markets for the notes. We do not intend to apply for
listing of the notes of any series on any securities exchange. Although the underwriters have advised us that they intend to make a market in the notes, they are not obligated to do so and may discontinue any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market-making at any time without notice. Accordingly, active trading markets may not develop for the notes and, even if any markets develop, may not be maintained. If active trading markets for
the notes do not develop or are not maintained, the market prices and liquidity of the notes are likely to be adversely affected, and holders may not be able to sell their notes at desired times and prices or at all. If any of the notes are traded
after their purchase, they may trade at a discount from their purchase prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The liquidity of the trading markets, if any, and future
trading prices of the notes will depend on many factors, including, among other things, prevailing interest rates, our financial condition, results of operations, business, prospects and credit quality, and those of comparable entities, the market
for similar securities and the overall securities market, and may be adversely affected by unfavorable changes in any of these factors, some of which are beyond our control. In addition, market volatility or events or developments in the credit
markets could materially and adversely affect the market value of the notes, regardless of our financial condition, results of operations, business, prospects or credit quality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the offering of the notes will be approximately $&#8195;&#8195;, after deducting the underwriting
discounts and estimated offering expenses payable by us. We intend to use the net proceeds of this offering to repay or redeem all of our 2025 Notes and to redeem or otherwise repurchase all of our 2026 Notes, in each case at or prior to their
respective maturities. The 2025 Notes bear interest at a rate of 5.350% per year and mature on October&nbsp;15, 2025 and the 2026 Notes bear interest at a rate of 4.900% per year and mature on February&nbsp;8, 2026. We intend to use the remainder of
net proceeds from this offering for working capital and for general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of other short-term and long-term debt, and the repurchase of our common stock pursuant to
our share repurchase program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and/or their respective affiliates and associated persons may own a portion of
the 2025 Notes and/or the 2026 Notes. If any of the underwriters, together with their respective affiliates and associated persons, receive at least 5% of the net proceeds from this offering, not including underwriting compensation, as a result of
our intended use of the net proceeds from the sale of the notes, such underwriters will be deemed to have a &#8220;conflict of interest&#8221; within the meaning of FINRA Rule 5121. However, pursuant to FINRA Rule 5121, the appointment of a
qualified independent underwriter is not necessary in connection with this offering because the notes are &#8220;investment grade rated&#8221; as defined by FINRA Rule 5121. See &#8220;<I>Underwriting (Conflicts of Interest)&#8212;Conflicts of
Interest</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_5"></A>SELECTED CONSOLIDATED HISTORICAL FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our financial information. We prepared this information using our unaudited consolidated financial statements
for the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2025 and 2024, and our audited consolidated financial statements for each of the years in the three-year period ended December&nbsp;31, 2024, which have been
audited by Ernst&nbsp;&amp; Young LLP. You should read this information in conjunction with our unaudited and audited consolidated financial statements and notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations included in our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ended June&nbsp;30, 2025, and our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended
December&nbsp;31, 2024, each of which is incorporated herein by reference. See &#8220;<I>Where You Can Find More Information</I>&#8221; on page S-28 of this prospectus supplement. In our opinion, the selected financial data for the <FONT
STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2025 and 2024, include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of that data. These selected consolidated historical
financial data do not necessarily indicate the results to be expected in the future. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;and for the Six<BR>Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2025<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2024<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2023<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2022<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(dollars in millions, except where indicated and except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income Statement Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating revenue<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#8217; net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#8217; Per Share Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Data (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit expense ratio<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expense ratio<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before income tax expense as a percentage of total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#8217; net income as a percentage of total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total medical membership (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and investments<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 35,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The net assets of and results of operations for each of Centers Plan for Healthy Living LLC and Centers for
Specialty Care Group IPA, LLC, RSV QOZB LTSS, Inc. (dba CareBridge), Paragon Healthcare, Inc., BioPlus Parent, LLC and Integra MLTC, Inc. (including each of their respective acquired affiliates) are included from their respective acquisition dates
of December&nbsp;31, 2024, December&nbsp;10, 2024, March&nbsp;11, 2024, February&nbsp;15, 2023 and May&nbsp;5, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operating revenue is obtained by adding premiums, product revenue, and service fees. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the six
months ended June&nbsp;30, 2025 and 2024 were $82,158 and $71,112, respectively. Premiums for the years ended December&nbsp;31, 2024, 2023 and 2022 were $144,166, $142,854 and $133,229, respectively. Premiums are included in total operating revenue
presented above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operating expense ratio represents operating expense as a percentage of total operating revenue.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash and investments is obtained by adding cash and cash equivalents, current and long-term fixed maturity
securities and equity securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_6"></A>DESCRIPTION OF THE NOTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Notes Will Be Issued Under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue $&#8195;&#8195; initial aggregate principal amount of &#8195;% notes due 2028, $&#8195;&#8195; initial aggregate principal amount
of &#8195;% notes due 2032, $&#8195;&#8195; initial aggregate principal amount of &#8195;% notes due 2036 and $&#8195;&#8195; initial aggregate principal amount of &#8195;% notes due 2055. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes will be issued under a senior note indenture dated as of November&nbsp;21, 2017 between us and The Bank of New York Mellon Trust
Company, N.A., as trustee. The trustee has two main roles. First, the trustee can enforce your rights against us if we default; however, there are some limitations on the extent to which the trustee acts on your behalf. Second, the trustee performs
administrative functions for us, such as sending you interest payments (as our paying agent), transferring your notes to a new buyer if you sell them (as our registrar) and sending you notices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the notes contain the full legal text of the matters described in this section. We have filed a copy of the indenture with
the SEC as an exhibit to our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed on November&nbsp;21, 2017. The indenture and the notes are governed by New York law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because this section is a summary, it does not describe every aspect of the notes and the indenture. This description is subject to, and
qualified in its entirety by, all the provisions of the indenture, including definitions of certain terms used in the indenture. For example, in this section we use capitalized words to signify defined terms that have been given special meaning in
the indenture. We describe the meaning for only the more important terms. We urge you to read the indenture and the notes because they, and not this description, define your rights as a holder of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of the Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2028 notes will
mature on &#8195;&#8195;&#8195;&#8195;&#8195;, 2028, the 2032 notes will mature on &#8195;&#8195;&#8195;&#8195;&#8195;, 2032, the 2036 notes will mature on &#8195;&#8195;&#8195;&#8195;&#8195;, 2036, and the 2055 notes will mature on
&#8195;&#8195;&#8195;&#8195;&#8195; , 2055. The notes will be our unsecured and unsubordinated obligations and will rank equally with all of our other unsecured and unsubordinated indebtedness from time to time outstanding. No sinking fund will be
provided with respect to the notes. The notes will not be convertible or exchangeable for other securities or property. No additional amounts will be payable with respect to the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each series of notes will be issued in fully registered form only, in minimum denominations of $1,000 or an integral multiple thereof. Each
series of notes will be issued in the form of one or more Global Securities, without coupons, which will be deposited initially with, or on behalf of, DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay interest on the 2028 notes, the 2032 notes and the 2055 notes from &#8195;&#8195;&#8195;&#8195;&#8195;, 2025 or from the most
recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually in arrears on &#8195;&#8195; and &#8195;&#8195; of each year, commencing &#8195;&#8195;&#8195;&#8195;&#8195;, 2026. We will pay interest on the 2036
notes from &#8195;&#8195;&#8195;&#8195;&#8195;, 2025 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually in arrears on &#8195;&#8195; and &#8195;&#8195; of each year, commencing
&#8195;&#8195;&#8195;&#8195;&#8195;, 2026. Interest on the 2028 notes, the 2032 notes and the 2055 notes will be paid to the persons in whose names such notes are registered at the close of business on &#8195;&#8195; or &#8195;&#8195; (whether or
not a Business Day), as the case may be, next preceding the relevant Interest Payment Date. Interest on the 2036 notes will be paid to the persons in whose names such notes are registered at the close of business on &#8195; &#8195; or &#8195;
&#8195; (whether or not a Business Day), as the case may be, next preceding the relevant Interest Payment Date. Interest on the notes will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT
STYLE="white-space:nowrap">30-day</FONT> months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Interest Payment Date or date of maturity of principal of the notes falls on a day
that is not a Business Day, then payment of interest or principal may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date, and no interest will accrue for the period after such nominal date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
(i)&nbsp;with respect to the 2028 notes, &#8195;&#8195;&#8195;&#8195;&#8195;, 2028 (one month prior to the maturity date of such notes), (ii) with respect to the 2032&nbsp;notes, &#8195;&#8195;&#8195;&#8195;&#8195;, 2032 (two months prior to the
maturity date of such notes), (iii) with respect to the 2036 notes, &#8195;&#8195;&#8195;&#8195;&#8195;, 2035 (three months prior to the maturity date of such notes), and (iv) with respect to the 2055 notes, &#8195;&#8195;&#8195;&#8195;&#8195;, 2055
(six months prior to the maturity date of such notes) (each such date, a &#8220;Par Call Date&#8221;), we may redeem the applicable series of notes at our option, in whole or in part, at any time and from time to time, at a redemption price
(expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed discounted to
the redemption date (assuming such notes matured on their applicable Par Call Date), on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months)
at the Treasury Rate (as defined below) plus &#8195;&#8195; basis points in the case of the 2028 notes, &#8195;&#8195; basis points in the case of the 2032 notes, &#8195;&#8195; basis points in the case of the 2036 notes, and&#8195;&#8195; basis
points in the case of the 2055 notes, less (b)&nbsp;interest accrued to the redemption date; and (2) 100% of the principal amount of the notes to be redeemed; plus, in either case, accrued and unpaid interest on the applicable notes to the
redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or after the applicable Par Call Date for the respective notes, we may redeem the notes of the applicable series in
whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon to such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing discussion of the applicable optional redemption provisions, the following definitions are applicable: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Treasury Rate</I>&#8221; means, with respect to any redemption date, the yield determined by us in accordance with the following two
paragraphs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Treasury Rate shall be determined by us after 4:15 p.m., New York City time (or after such time as yields on U.S.
government securities are posted daily by the Board of Governors of the Federal Reserve System), on the third business day preceding the redemption date based upon the yield or yields for the most recent day that appear after such time on such day
in the most recent statistical release published by the Board of Governors of the Federal Reserve System designated as &#8220;Selected Interest Rates (Daily)&#8212;H.15&#8221; (or any successor designation or publication) (&#8220;H.15&#8221;) under
the caption &#8220;U.S. government securities&#8212;Treasury constant maturities&#8212;Nominal&#8221; (or any successor caption or heading) (&#8220;H.15 TCM&#8221;). In determining the Treasury Rate, we shall select, as applicable: (1)&nbsp;the
yield for the Treasury constant maturity on H.15 exactly equal to the period from the redemption date to the applicable Par Call Date (the &#8220;Remaining Life&#8221;); or (2)&nbsp;if there is no such Treasury constant maturity on H.15 exactly
equal to the Remaining Life, the two yields &#8211; one yield corresponding to the Treasury constant maturity on H.15 immediately shorter than and one yield corresponding to the Treasury constant maturity on H.15 immediately longer than the
Remaining Life &#8211; and shall interpolate to the applicable Par Call Date on a straight-line basis (using the actual number of days) using such yields and rounding the result to three decimal places; or (3)&nbsp;if there is no such Treasury
constant maturity on H.15 shorter than or longer than the Remaining Life, the yield for the single Treasury constant maturity on H.15 closest to the Remaining Life. For purposes of this paragraph, the applicable Treasury constant maturity or
maturities on H.15&nbsp;shall be deemed to have a maturity date equal to the relevant number of months or years, as applicable, of such Treasury constant maturity from the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If on the third business day preceding the redemption date H.15 TCM is no longer published, we shall calculate the Treasury Rate based on the
rate per annum equal to the semi-annual equivalent yield to maturity at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
11:00 a.m., New York City time, on the second business day preceding such redemption date of the United States Treasury security maturing on, or with a maturity that is closest to, the applicable
Par Call Date, as applicable. If there is no United States Treasury security maturing on such Par Call Date but there are two or more United States Treasury securities with a maturity date equally distant from such Par Call Date, one with a maturity
date preceding such Par Call Date and one with a maturity date following such Par Call Date, we shall select the United States Treasury security with a maturity date preceding such Par Call Date. If there are two or more United States Treasury
securities maturing on such Par Call Date or two or more United States Treasury securities meeting the criteria of the preceding sentence, we shall select from among these two or more United States Treasury securities the United States Treasury
security that is trading closest to par based upon the average of the bid and asked prices for such United States Treasury securities at 11:00 a.m., New York City time. In determining the Treasury Rate in accordance with the terms of this paragraph,
the semi-annual yield to maturity of the applicable United States Treasury security shall be based upon the average of the bid and asked prices (expressed as a percentage of principal amount) at 11:00 a.m., New York City time, of such United States
Treasury security, and rounded to three decimal places. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actions and determinations in determining the redemption price shall be
conclusive and binding for all purposes, absent manifest error. We will notify the trustee of the redemption price promptly after the calculation thereof and the trustee shall not be responsible or liable for any calculation of the redemption price
or of any component thereof, or for determining whether manifest error has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any redemption will be mailed or
electronically delivered (or otherwise transmitted in accordance with the depositary&#8217;s procedures) at least 10 days but not more than 60 days before the redemption date to each holder of notes to be redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a partial redemption, selection of the notes for redemption will be made pro rata, by lot or by such other method as the
trustee in its sole discretion deems appropriate and fair. No notes of a principal amount of $1,000 or less will be redeemed in part. If any note is to be redeemed in part only, the notice of redemption that relates to the note will state the
portion of the principal amount of the note to be redeemed. Except in the case of global notes, a new note in a principal amount equal to the unredeemed portion of the note will be issued in the name of the holder of the note upon surrender for
cancellation of the original note. In the case of global notes, DTC will determine the allocation of the redemption price among beneficial owners in such global notes in accordance with DTC&#8217;s applicable procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions
thereof called for redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above and below under &#8220;<I>Repurchase Upon a Change of Control</I>,&#8221; the
notes will not be redeemable by us prior to maturity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchase Upon a Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Change of Control Triggering Event (defined below) occurs with respect to a particular series of notes, unless we have exercised our right
to redeem the notes of that series in full, as described above, we will make an offer to each holder of the notes of such series (the &#8220;Change of Control Offer&#8221;) to repurchase any and all (equal to $1,000 or an integral multiple thereof)
of such holder&#8217;s notes of such series at a repurchase price in cash equal to 101% of the principal amount of the notes repurchased plus accrued and unpaid interest, if any, thereon, to the date of purchase (the &#8220;Change of Control
Payment&#8221;). Within 30 days following any Change of Control Triggering Event, we will be required to mail a notice to holders of notes of the relevant series describing the transaction or transactions that constitute the Change of Control
Triggering Event and offering to repurchase the notes of such series on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (the &#8220;Change of Control Payment
Date&#8221;), pursuant to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures required by the notes of such series and described in such notice. We must comply with the requirements of <FONT STYLE="white-space:nowrap">Rule&nbsp;14e-1</FONT> under the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes of such series as a
result of a Change of Control Triggering Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of Control repurchase provisions of the relevant notes, we will be required to comply with the
applicable securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control repurchase provisions of such notes by virtue of such conflicts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Change of Control Payment Date, we will be required, to the extent lawful, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or
portions of notes properly tendered; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver or cause to be delivered to the trustee the notes properly accepted, together with an officer&#8217;s
certificate stating the principal amount of notes or portions of notes being purchased. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The definition of Change of
Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance or other disposition of &#8220;all or substantially all&#8221; of the properties or assets of Elevance Health and its subsidiaries taken as a whole.
Although there is a limited body of case law interpreting the phrase &#8220;substantially all,&#8221; there is no precise established definition of the phrase under applicable law. Accordingly, the applicability of the requirement that we offer to
repurchase the notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of the assets of Elevance Health and its subsidiaries taken as a whole to another Person (as defined in the indenture) or group may be
uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing discussion of the applicable Change of Control provisions, the following definitions are
applicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Below Investment Grade Rating Event</I>&#8221; means the notes of the applicable series are rated below an
Investment Grade Rating by each of the Rating Agencies (as defined below) on any date from the date of the public notice of an arrangement that could reasonably be expected to result in a Change of Control until the end of the <FONT
STYLE="white-space:nowrap">60-day</FONT> period following public notice of the occurrence of the Change of Control (which <FONT STYLE="white-space:nowrap">60-day</FONT> period shall be extended so long as the rating of the notes is under publicly
announced consideration for possible downgrade by any of the Rating Agencies); <I>provided, however, that </I>a Below Investment Grade Rating Event otherwise arising by virtue of a particular reduction in rating will not be deemed to have occurred
in respect of a particular Change of Control Triggering Event (and thus will not be deemed a Below Investment Grade Rating Event for purposes of the definition of Change of Control Triggering Event) if the rating agencies making the reduction in
rating to which this definition would otherwise apply do not announce or publicly confirm or inform the trustee in writing at our request that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as
a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control has occurred at the time of the Below Investment Grade Rating Event). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Change of Control</I>&#8221; means the occurrence of any of the following: (1)&nbsp;direct or indirect sale, transfer, conveyance or
other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of Elevance Health and its subsidiaries taken as a whole to any
&#8220;person&#8221; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act) other than to Elevance Health or one of its subsidiaries; (2)&nbsp;the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any &#8220;person&#8221; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act) becomes the beneficial owner, directly or indirectly, of more than 50% of the then outstanding number of shares
of Elevance Health&#8217;s voting stock; or (3)&nbsp;the first day on which a majority of the members of Elevance Health&#8217;s Board of Directors are not Continuing Directors; <I>provided, however, that </I>a transaction will not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be deemed to involve a Change of Control if we become a wholly owned subsidiary of a holding company and the holders of the voting stock of such holding company immediately following that
transaction are substantially the same as the holders of our voting stock immediately prior to that transaction. For purposes of this definition, &#8220;voting stock&#8221; means capital stock of any class or kind the holders of which are
ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of Elevance Health, even if the right to vote has been suspended by the happening of such a contingency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Change of Control Triggering Event</I>&#8221; means the occurrence of both a Change of Control and a Below Investment Grade Rating
Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Continuing Directors</I>&#8221; means, as of any date of determination, any member of the Board of Directors of Elevance
Health who (1)&nbsp;was a member of the Board of Directors of Elevance Health on the date of the issuance of the notes; or (2)&nbsp;was nominated for election or elected to the Board of Directors of Elevance Health with the approval of a majority of
the Continuing Directors who were members of such Board of Directors of Elevance Health at the time of such nomination or election (either by specific vote or by approval of Elevance Health&#8217;s proxy statement in which such member was named as a
nominee for election as a director, without objection to such nomination). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Fitch</I>&#8221; means Fitch Ratings, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Investment Grade Rating</I>&#8221; means a rating by Moody&#8217;s equal to or higher than Baa3 (or the equivalent under a successor
rating category of Moody&#8217;s), a rating by S&amp;P equal to or higher than <FONT STYLE="white-space:nowrap">BBB-</FONT> (or the equivalent under any successor rating category of S&amp;P) or a rating by Fitch equal to or higher than <FONT
STYLE="white-space:nowrap">BBB-</FONT> (or the equivalent under any successor rating category of Fitch), or a rating by a replacement Rating Agency, if applicable, substantially equivalent to the foregoing ratings or higher. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Moody&#8217;s</I>&#8221; means Moody&#8217;s Ratings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>Rating Agencies</I>&#8221; means (1)&nbsp;Moody&#8217;s, S&amp;P and Fitch; and (2)&nbsp;if any or all of Moody&#8217;s, S&amp;P or
Fitch ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Rule <FONT
STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act, selected by us (as certified by a resolution of our Board of Directors) as a replacement agency for any of Moody&#8217;s, S&amp;P or Fitch, or all of them, as the case may
be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<I>S&amp;P</I>&#8221; means S&amp;P Global Ratings, a division of S&amp;P Global Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We May Issue Other Series of Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture permits us to issue different series of debt securities from time to time. The specific terms of each other series that we may
issue in the future may differ from those of the notes. The indenture does not limit the aggregate amount of debt securities that may be issued under the indenture, nor does it limit the number of other series or the aggregate amount of any
particular series. The 2028 notes will be limited initially to $&#8195;&#8195; aggregate principal amount, the 2032 notes will be limited initially to $&#8195;&#8195; aggregate principal amount, the 2036 notes will be limited initially to
$&#8195;&#8195; aggregate principal amount and the 2055 notes will be limited initially to $&#8195;&#8195; aggregate principal amount. We may <FONT STYLE="white-space:nowrap">&#8220;re-open&#8221;</FONT> any series of notes at any time without the
consent of the noteholders. We may issue additional securities from time to time after this offering. The notes of any series and any additional new notes at any time of such series subsequently issued under the indenture would be treated as a
single series for all purposes under the indenture, including, without limitation, waivers, amendments, redemptions and offers to purchase; provided that if such additional notes are not fungible with such notes for U.S. federal income tax purposes,
the additional notes will have a separate CUSIP number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the notes do not limit our ability to incur other debt or to issue other
securities. When we refer to a series of debt securities, we mean a series, such as each of the series of notes we are offering by means of this prospectus supplement and the accompanying prospectus, issued under the indenture. When we refer to the
notes or these notes, we mean each series of notes we are offering by means of this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes may be defeased, at our option, through legal defeasance or covenant defeasance as provided for in the indenture and as
described in the accompanying prospectus under the captions &#8220;<I>Description of the Debt Securities&#8212;Defeasance</I>&#8221; and &#8220;<I>Description of the Debt Securities&#8212;Satisfaction and Discharge</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each series of notes
will be issued in the form of one or more global notes in definitive, fully registered form, without interest coupons (the &#8220;Global Note&#8221;). Each Global Note&nbsp;will be deposited with the trustee, as custodian for, and registered in the
name of a nominee of, DTC as depository, and will be held through the book-entry system of DTC and its participants, including Euroclear and Clearstream. See &#8220;<I>Description of the Debt Securities&#8212;Global Notes, Delivery and
Form</I>&#8221; in the accompanying prospectus for a description of registered Global Notes held in book entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue debt
securities in definitive form in exchange for a Global Note only in the following situations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Depository is at any time unwilling or unable to continue as depository and a successor depository is not
appointed by us within 120 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to DTC procedures, if we choose to issue definitive debt securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if there is an Event of Default and there is a request from the Depository or any holder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any such instance, an owner of a beneficial interest in a Global Note&nbsp;will be entitled to have debt securities equal in principal
amount to that beneficial interest registered in its name and will be entitled to physical delivery of debt securities in definitive form. Debt securities in definitive form will be issued in denominations of $1,000 or an integral multiple thereof
and will be issued in registered form only, without coupons. We will maintain in the Borough of Manhattan, The City of New York, one or more offices or agencies where debt securities may be presented for payment and may be transferred or exchanged.
You will not be charged a fee for any transfer or exchange of debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_7"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes certain material U.S. federal income tax consequences of ownership and disposition of the notes. This
discussion applies only to notes that are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchased by those beneficial owners of notes who purchase notes for cash in this offering at the &#8220;issue
price,&#8221; which will equal the first price at which a substantial amount of the notes of the same series is sold to the public; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">held as capital assets within the meaning of section 1221 of the Code (as defined below). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not describe all of the tax consequences that may be relevant to a holder in light of the holder&#8217;s particular
circumstances or to holders subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding notes as part of a hedge, &#8220;straddle,&#8221; integrated transaction or similar transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities classified as partnerships for U.S. federal income tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accrual method taxpayers required to recognize income no later than when such income is taken into account for
financial accounting purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes
holds notes, the U.S.&nbsp;federal income tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. Partnerships holding notes and partners in such partnerships should consult their tax
advisors as to the particular U.S. federal income tax consequences to them of holding and disposing of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is based
on the Internal Revenue Code of 1986, as amended, or the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations, changes to any of which subsequent to the date of this prospectus supplement may
affect the tax consequences described herein. This summary is not binding on the courts or the Internal Revenue Service, or the IRS, and there can be no assurance that the IRS will not challenge one or more of the tax consequences described herein,
and we have not obtained, nor do we intend to obtain, a ruling from the IRS with respect to the U.S. federal income tax consequences of purchasing, owning or disposing of the notes. Persons considering the purchase of notes are urged to consult
their tax advisors with regard to the application of the U.S. federal income tax laws to their particular situations as well as any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the effect of any federal taxes other than income taxes (e.g., federal estate or gift taxes or the Medicare
tax on certain investment income) or any state, local or foreign taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchase Upon a Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to take the position that the possibility of the payment of additional amounts above the principal amount of the notes described in
&#8220;<I>Description of the Notes&#8212;Repurchase Upon a Change of Control</I>,&#8221; if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, is remote and therefore will not cause the notes to be considered &#8220;contingent payment debt instruments&#8221; under applicable Treasury Regulations. Our position is binding on
you unless you disclose that you are taking a contrary position in the manner required by applicable Treasury Regulations. Our position is not, however, binding on the IRS, and if the IRS were to challenge this position, you might be required to use
the accrual method, even if you were otherwise a cash method taxpayer, to accrue income on the notes in excess of the stated interest on the notes, and to treat as ordinary income rather than capital gain any income that you realize on the taxable
disposition of a note. The remainder of this discussion assumes that the notes will not be considered contingent payment debt instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax
Consequences to U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#8220;<I>U.S. Holder</I>&#8221; means a beneficial owner of a note that is, for
U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any State thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if (a)&nbsp;a court within the United States is able to exercise primary supervision over administration
of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust, or (b)&nbsp;the trust was in existence on August&nbsp;20, 1996 and has a valid election to be treated as a U.S. person in effect under
applicable U.S. Treasury Regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments of interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is anticipated, and the following discussion assumes, that the notes will be issued in this offering with no more than a <I>de minimis
</I>amount of original issue discount. Interest payable on a note will be taxable to a U.S.&nbsp;Holder as ordinary interest income at the time it accrues or is received in accordance with the U.S. Holder&#8217;s method of accounting for U.S.
federal income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, exchange or other disposition of the notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the sale, exchange or other taxable disposition of a note, a U.S. Holder will recognize taxable gain or loss equal to the difference
between the amount realized on the sale, exchange or other taxable disposition and the U.S. Holder&#8217;s tax basis in the note (generally the price paid by the U.S. Holder to purchase the note). For these purposes, the amount realized does not
include an amount equal to the accrued but unpaid interest on the note, which will be treated as interest as described under &#8220;<I>Payments of interest</I>&#8221; above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain or loss realized on the sale, exchange or other taxable disposition of a note will generally be capital gain or loss and will be
long-term capital gain or loss if at the time of the sale, exchange or other taxable disposition the note has been held by the U.S. Holder for more than one year. Long-term capital gains recognized by
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders (including individuals) generally are subject to U.S. federal income taxation at preferential rates. The deductibility of capital losses is subject to limitations under the Code.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup withholding and information reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments on the notes and the proceeds from a sale or other disposition of
the notes to certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders. A U.S. Holder will be subject to U.S. backup withholding on these payments if the U.S. Holder fails to provide its taxpayer identification number to the paying
agent and comply with certain certification procedures or otherwise establish an exemption from backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle the U.S. Holder to a refund, <I>provided that </I>the
required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#8220;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder</I>&#8221; means a beneficial owner of a note that
is not a U.S. Holder and is not a partnership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments of interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below concerning backup withholding and FATCA (as defined below), payments of interest on the notes by us or any
paying agent to any <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct of a trade or business within the United States will not
be subject to U.S. federal income or withholding tax, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder does not own, actually or constructively, 10% or more
of the total combined voting power of all classes of our stock entitled to vote, and is not a controlled foreign corporation related, directly or indirectly, to us through stock ownership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not a bank whose receipt of interest on the notes
is described in Section&nbsp;881(c)(3)(A) of the Code; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies on IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable, under penalties of perjury, that it is not a United States person or holds its notes through
various foreign intermediaries and satisfies the certification requirements of applicable Treasury Regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event that a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder does not meet the foregoing requirements, interest on the notes that is not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct
of a trade or business within the United States will be subject to the 30% U.S. federal withholding tax (or lower rate under an applicable income tax treaty). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is engaged in a trade or business in the United States and interest on the note
is effectively connected with the conduct of such trade or business, and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or a fixed base of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder, the <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;Holder</FONT> will generally be taxed in the same manner as a U.S. Holder (see &#8220;<I>&#8212;Tax Consequences to U.S. Holders</I>&#8221; above), subject to an applicable income tax treaty
providing otherwise. Such a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide a properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> in order to claim an exemption from withholding tax on
interest. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders whose interest derived from the notes may be effectively connected with the conduct of a trade or business in the United States are urged to consult their own tax advisors with
respect to the U.S. tax consequences of the ownership and disposition of notes, including the possible imposition of an additional branch profits tax, currently at a rate of 30% (or lower rate under an applicable income tax treaty), on <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are corporations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, exchange or other disposition of the notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions of backup withholding and FATCA withholding below, U.S. federal income or withholding tax generally will not apply
to any gain that a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder realizes on the sale, exchange, redemption, retirement or other taxable disposition of a note unless (i)&nbsp;that gain is effectively connected with the conduct of a trade
or business in the United States by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base of the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States for a period or periods aggregating 183 days or more in the taxable year
of that disposition and other conditions are met. If clause (i)&nbsp;applies, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal income tax on the net gain derived from the disposition generally
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the same manner as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a U.S. Holder, and if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a corporation, such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to a branch profits tax equal to 30% (or lower applicable treaty rate) as described above. If clause (ii)&nbsp;applies, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder will be subject to a flat 30% tax (or&nbsp;lower applicable treaty rate) on the gain derived from the sale, exchange, redemption, retirement or other taxable disposition, which may be offset by certain U.S. source capital losses, even though
such holder is not considered a resident of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup withholding and information reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with interest payments on the notes. Copies of the information returns may also be
made available to the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;Holder</FONT> resides under the provisions of an applicable income tax treaty or applicable tax information exchange agreement. Unless
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder complies with certification procedures to establish that it is not a United&nbsp;States person, information returns may be filed with the IRS in connection with the proceeds from a sale or
other disposition of the notes and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be subject to U.S. backup withholding on payments on the notes or on the proceeds from a sale or other disposition of the notes within the United
States or conducted through certain U.S.-related financial intermediaries. Compliance with the certification procedures required to claim the exemption from withholding tax on interest described above will satisfy the certification requirements
necessary to avoid backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be allowed as a credit against the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s U.S. federal income tax liability, if any, and may entitle the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to a refund, <I>provided that </I>the required information is timely
furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Sections 1471 to 1474 of the Code and the Treasury Regulations promulgated thereunder (the&nbsp;provisions commonly known as
FATCA), interest paid on the notes to a foreign financial institution (whether&nbsp;such foreign financial institution is a beneficial owner or an intermediary) may be subject to U.S.&nbsp;federal withholding tax at a rate of 30% unless (x)(1) such
institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain
equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or (2)&nbsp;such institution resides in a jurisdiction with which the United&nbsp;States has entered into an
intergovernmental agreement to implement FATCA and (y)&nbsp;such foreign financial institution provides the withholding agent with a certification that it is eligible to receive payment free of FATCA withholding. FATCA also generally will impose a
U.S. federal withholding tax of 30% on interest paid on the notes to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity (whether such <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity is a beneficial owner or
an intermediary) unless such entity provides the withholding agent with a certification (i)&nbsp;that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&nbsp;provides certain information regarding the entity&#8217;s
&#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. tax authorities. While withholding under FATCA would have applied to payments of gross proceeds from the sale or other disposition of notes on or after
January&nbsp;1, 2019, proposed Treasury Regulations eliminated FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. A foreign
financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity can meet the certification requirements by providing a properly executed applicable <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8.</FONT> Under
certain circumstances, a U.S. Holder or <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder might be eligible for refunds or credits of such taxes from the IRS. An applicable intergovernmental agreement regarding FATCA between the United States
and the jurisdiction of a foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity may modify the rules discussed in this paragraph. Prospective investors are encouraged to consult with their own tax
advisors regarding the possible implications of this legislation on their investment in any of the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_8"></A>UNDERWRITING (Conflicts of Interest) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering the notes described in this prospectus supplement through a number of underwriters. BofA Securities, Inc., Deutsche Bank
Securities Inc. and Mizuho&nbsp;Securities USA LLC are the representatives of the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has agreed to
purchase, severally and not jointly, the aggregate principal amount of notes listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal</B><br><B>Amount of</B><br><B>2028&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal</B><br><B>Amount of</B><br><B>2032&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal</B><br><B>Amount of</B><br><B>2036&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Principal</B><br><B>Amount of</B><br><B>2055&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deutsche Bank Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement is subject to a number of terms and conditions and provides that the underwriters
must buy all of the notes if they buy any of them. The underwriters will sell the notes to the public when and if the underwriters buy the notes from us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they propose to initially offer the notes to the public for cash at the public offering prices set forth
on the cover of this prospectus supplement, and that they may offer the notes to certain dealers at such price less concessions not in excess of &#8195;% of the principal amount of the 2028 notes, &#8195;% of the principal amount of the 2032 notes,
&#8195;% of the principal amount of the 2036 notes, and &#8195;% of the principal amount of the 2055 notes. The underwriters may allow, and such dealers may reallow, a concession not in excess of &#8195;% of the principal amount of the 2028 notes,
&#8195;% of the principal amount of the 2032 notes, &#8195;% of the principal amount of the 2036 notes, and &#8195;% of the principal amount of the 2055 notes to certain other dealers. After the public offering of the notes, the public offering
prices and other selling terms may be changed. The offering of the notes by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our share of the total expenses of the offering, excluding underwriting discounts, will be approximately
$&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against, or contribute to payments that the underwriters may
be required to make in respect of, certain liabilities, including liabilities under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are
new issues of securities with no established trading market. The notes will not be listed on any securities exchange or on any automated dealer quotation system. Although the underwriters have advised us that they intend to make a market in each
series of the notes after completion of the offering, they are not obligated to do so and may discontinue any market-making activities at any time without notice. No assurance can be given as to the liquidity of the trading markets for the notes or
that an active public market for any series of the notes will develop. If active public markets for the notes do not develop, the market prices and liquidity of the notes may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of the notes, certain of the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the prices of the notes. In addition, the underwriters may bid for, and purchase, the notes in the open market to cover short positions or to stabilize the prices of the notes. Any of these activities may stabilize or maintain the market
prices of the notes above independent market levels, but no representation is made hereby of the magnitude of any effect that the transactions described above may have on the market prices of the notes. The underwriters will not be required to
engage in these activities, and may engage in these activities, and may end any of these activities, at any time without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters also may impose a penalty bid. This occurs when a particular underwriter
repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased notes sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Settlement Cycle </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that
delivery of the notes will be made against payment therefor on or about the date specified in the last paragraph of the cover page of this prospectus supplement (the &#8220;closing date&#8221;), which will be the fifth business day following the
date of the pricing of the notes (such settlement being referred to as &#8220;T&#043;5&#8221;). Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> under the Exchange Act, trades in the secondary market are generally required to settle in one
business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the first business day preceding the closing date will be required, by virtue of the fact that the notes will
initially settle in T&#043;5, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts
of Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds of this offering to repay or redeem all of our 2025 Notes and to redeem or otherwise
repurchase all of our 2026 Notes, in each case at or prior to their respective maturities, and to use the remainder of net proceeds for working capital and for general corporate purposes, including, but not limited to, the funding of acquisitions,
repayment of other short-term and long-term debt, and the repurchase of our common stock pursuant to our share repurchase program. See &#8220;<I>Use of Proceeds</I>.&#8221; Certain of the underwriters and/or their respective affiliates and
associated persons may own a portion of the 2025 Notes and/or the 2026 Notes. If any of the underwriters, together with their respective affiliates and associated persons, receive at least 5% of the net proceeds from this offering, not including
underwriting compensation, as a result of our intended use of the net proceeds from the sale of the notes, such underwriters will be deemed to have a &#8220;conflict of interest&#8221; within the meaning of FINRA Rule 5121. However, pursuant to
FINRA Rule 5121, the appointment of a qualified independent underwriter is not necessary in connection with this offering because the notes are &#8220;investment grade rated&#8221; as defined by FINRA Rule&nbsp;5121. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made
available to any retail investor in the European Economic Area (&#8220;EEA&#8221;). For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as defined in point (11)&nbsp;of Article&nbsp;4(1) of
Directive 2014/65/EU (as amended, &#8220;MiFID II&#8221;); or (ii)&nbsp;a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a professional client as defined in point (10)&nbsp;of
Article&nbsp;4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Regulation 2017/1129/EU (as&nbsp;amended, the &#8220;Prospectus Regulation&#8221;). Consequently, no key information document required by Regulation (EU) No
1286/2014 (as amended, the &#8220;PRIIPs Regulation&#8221;) for offering or selling the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them
available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of notes in any Member State of the EEA will be made
pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of notes. This prospectus supplement and the accompanying prospectus are not a prospectus for the purposes of the Prospectus Regulation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not intended to constitute an offer or solicitation to purchase or invest in the notes. The notes may not be
publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#8220;FinSA&#8221;) and no application has or will be made to admit the notes to trading on any trading venue (exchange or multilateral
trading facility) in Switzerland. Neither this prospectus supplement nor any other offering or marketing material relating to the notes constitutes a prospectus pursuant to the FinSA, and neither this prospectus supplement nor any other offering or
marketing material relating to the notes may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made
available to any retail investor in the United Kingdom (&#8220;UK&#8221;). For these purposes, a retail investor means a person who is one (or more) of (i)&nbsp;a retail client, as defined in point (8)&nbsp;of Article&nbsp;2 of Regulation (EU)
2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act&nbsp;2018 (&#8220;EUWA&#8221;); (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (as amended, the
&#8220;FSMA&#8221;) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97 (as amended or superseded), where that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article&nbsp;2(1) of
Regulation (EU) 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii)&nbsp;not a qualified investor as defined in Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA (the &#8220;UK Prospectus
Regulation&#8221;). Consequently, no key information document required by Regulation (EU) 1286/2014 as it forms part of domestic law by virtue of the EUWA (the &#8220;UK PRIIPs Regulation&#8221;) for offering or selling the notes or otherwise making
them available to retail investors in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of notes in the UK will be made
pursuant to an exemption under the UK Prospectus Regulation and the FSMA from the requirement to publish a prospectus for offers of notes. This prospectus supplement and the accompanying prospectus are not a prospectus for the purposes of the UK
Prospectus Regulation or the FSMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters
relating to investments and who qualify as investment professionals within the meaning of Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#8220;Financial Promotion Order&#8221;),
(ii) are persons falling within Article&nbsp;49(2)(a) to (d) (&#8220;high net worth companies, unincorporated associations etc.&#8221;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom, or (iv)&nbsp;are persons to whom an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such
persons together being referred to as &#8220;relevant persons&#8221;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which
this document relates is available only to relevant persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes may not be offered or sold by means of any document other than: (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong&nbsp;Kong), or (ii)&nbsp;to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made
thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), and no advertisement, invitation or document relating
to the notes may be issued or may be in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public
in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; within the meaning
of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, the notes may not be offered or sold, or made the subject of an invitation for subscription or purchase, nor may this prospectus supplement, the accompanying prospectus or any other document or material in connection with the offer or
sale, or invitation for subscription or purchase of the notes be circulated, whether directly or indirectly, to any person in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act
2001 of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&nbsp;274 of the SFA or (ii)&nbsp;to an accredited investor (as defined in Section&nbsp;4A of the SFA) pursuant to and in accordance with the
conditions specified in Section&nbsp;275 of the SFA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (the &#8220;Financial Instruments
and Exchange Law&#8221;) and each underwriter has agreed that it will not offer or sell any notes, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan,
including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption
from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes may be sold only
to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act
(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made in accordance with
an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or
damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the
purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of
National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT
STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates are full service financial institutions that have engaged in, and may in the future engage in,
investment banking and other commercial dealings in the ordinary course of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. Certain affiliates of underwriters are participants in
our revolving credit agreement. In addition, certain underwriters or their affiliates may hold positions in our outstanding notes. As a result, the underwriters or their affiliates may receive a portion of the proceeds from this offering if we use
the proceeds to repay any of our outstanding indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their business activities, the underwriters and
their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. If the underwriters or their affiliates have a lending relationship with us, certain of those underwriters or their affiliates
routinely hedge, and certain other of those underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, the underwriters and their affiliates would hedge such exposure
by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the notes offered hereby. Any such credit default swaps or short positions could
adversely affect future trading prices of the notes offered hereby. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the notes and specified legal matters in connection with this offering will be passed upon for us by Hogan Lovells US LLP.
Davis Polk&nbsp;&amp; Wardwell LLP will act as counsel for the underwriters. Certain legal matters relating to Indiana law will be passed upon for us by Faegre Drinker Biddle&nbsp;&amp; Reath LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and schedule of Elevance Health appearing in Elevance Health&#8217;s Annual Report <FONT
STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2024, and the effectiveness of Elevance Health&#8217;s internal control over financial reporting as of December&nbsp;31, 2024, have been audited by
Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon, and incorporated herein by reference. Such consolidated financial statements and schedule are incorporated herein by reference in
reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains
reports, proxy and information statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is <I><U>http://www.sec.gov</U></I>. The reports and other information filed by us with the
SEC are also available at our website. The address of our website is <I><U>www.elevancehealth.com</U></I>. We are not incorporating the contents of our website into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should also be able to inspect reports, proxy statements and other information about us at the offices of the New York Stock Exchange, 11
Wall Street, New York, New York 10005. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
with the SEC covering the securities that may be sold under this prospectus supplement and the accompanying prospectus. For further information on us and the securities, you should refer to our registration statement and its exhibits. This
prospectus supplement and the accompanying prospectus summarize material provisions of contracts and other documents to which we refer you. Because the prospectus supplement and the accompanying prospectus may not contain all the information that
you may find important, you should review the full text of these documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="s11296_12"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus supplement and the accompanying prospectus information
contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and the
accompanying prospectus, and information that we file after the date of this prospectus supplement with the SEC will automatically update and supersede this information. We specifically incorporate by reference the following documents, which we have
already filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000010/elv-20241231.htm">December
<U></U>&nbsp;31, 2024</A> (the &#8220;Annual Report&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000057/elv-20250331.htm">March
<U></U>&nbsp;31, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000114/elv-20250630.htm">June<U></U>&nbsp;30, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the portions of our Definitive Proxy Statement on Schedule 14A filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000046/elv-20250328.htm">March
<U></U>&nbsp;28, 2025</A>, incorporated by reference into the Annual Report; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000065/elv-20250514.htm">May
<U></U>&nbsp;14, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603925000118/elv-20250728.htm">July<U></U>&nbsp;28, 2025</A>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and
before all of the securities offered by this prospectus supplement are sold are incorporated by reference in this prospectus supplement from the date of filing of the documents, except for information &#8220;furnished&#8221; under Item 2.02 and Item
7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other information &#8220;furnished&#8221; to the SEC, which is not deemed filed and not incorporated by reference herein. Information that we file with the SEC will automatically update and
may replace information in this prospectus supplement and information previously filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge to
each person, including any beneficial owner, to whom this prospectus supplement is delivered, upon written or oral request, a copy of any or all of the foregoing documents and any other documents that are incorporated herein by reference (other than
exhibits unless such exhibits are specifically incorporated by reference in such documents). Requests for such documents should be directed to our Corporate Secretary at our principal executive office, located at: 220 Virginia Avenue, Indianapolis,
Indiana&nbsp;46204, Telephone (833) <FONT STYLE="white-space:nowrap">401-1577.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g11296g60s01.jpg" ALT="LOGO" STYLE="width:2.71875in;height:1.16667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SENIOR DEBT SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SUBORDINATED DEBT SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON
STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>STOCK PURCHASE UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
may offer and sell, from time to time, one or any combination of the securities we describe in this prospectus. The debt securities and our preferred stock we may offer may be convertible into or exchangeable for our common stock or our other
securities, or debt or equity securities of one or more other entities. When we offer securities, we will provide you with a prospectus supplement describing the terms of the specific issue of securities including the offering price of the
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the prospectus supplement relating to the specific issue of securities carefully before
you invest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell these securities to or through one or more underwriters, dealers or agents, or directly to purchasers,
on a continuous or delayed basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ELV.&#8221; Any
common stock sold pursuant to a prospectus supplement will be listed, subject to notice of issuance, on the New York Stock Exchange. If we decide to list or seek a quotation for any other securities we may offer and sell from time to time, the
prospectus supplement relating to those securities will disclose the exchange or market on which those securities will be listed or quoted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risks. You should carefully consider the risks described under &#8220;<A HREF="#srom11296_25">Risk Factors</A>&#8221; on page&nbsp;4&nbsp;of this prospectus, as well as the other information contained or incorporated by reference in this prospectus and the applicable prospectus supplement, before making a decision to invest in our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
prospectus is November&nbsp;1, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_20">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_21">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_23">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_24">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_25">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_26">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_27">DESCRIPTION OF THE DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_28">DESCRIPTION OF THE PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_29">DESCRIPTION OF THE COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_30">DESCRIPTION OF THE DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_31">DESCRIPTION OF THE WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_32">DESCRIPTION OF THE RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_33">DESCRIPTION OF THE STOCK PURCHASE CONTRACTS AND STOCK PURCHASE
UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_34">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_35">VALIDITY OF THE SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom11296_36">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_20"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#8220;shelf&#8221; registration process. Under this shelf process, we may sell any combination of the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities we may
offer. Each time we offer to sell any of the securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering and the securities being offered. The prospectus supplement may also add, update
or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement together with the additional information described under the headings &#8220;<I>Where You Can Find More
Information</I>&#8221; and &#8220;<I>Incorporation of Certain Documents by Reference</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, the terms
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;Elevance Health&#8221; refer to Elevance Health, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_21"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents incorporated by reference herein, contains &#8220;forward-looking statements&#8221; within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are intended to be covered by the safe
harbor for &#8220;forward-looking statements&#8221; provided by the Private Securities Litigation Reform Act of 1995. Words such as &#8220;expect(s),&#8221; &#8220;feel(s),&#8221; &#8220;believe(s),&#8221; &#8220;will,&#8221; &#8220;may,&#8221;
&#8220;anticipate(s),&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project&#8221; and similar expressions are intended to identify forward-looking statements, which generally are not historical in nature. Forward-looking statements
include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future
performance. Such forward-looking statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You should carefully review the risks and information
contained, or incorporated by reference, in this prospectus or any applicable prospectus supplement, including, without limitation, the &#8220;Risk Factors&#8221; beginning on page&nbsp;4&nbsp;herein and incorporated by reference herein from
our&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001156039/000115603923000007/elv-20221231.htm">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December<U></U>&nbsp;
31, 2022</A>&nbsp;and other reports and information that we file from time to time in the future with the SEC. Except to the extent otherwise required by federal securities law, we do not undertake any obligation to republish revised forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with
the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC. The address of that site is http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also make available, free of charge, on or through our website (http://www.elevancehealth.com), our Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> Proxy Statements on Schedule 14A and, if applicable, amendments to
those reports filed or furnished pursuant to Section&nbsp;13(a) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Please note, however, that we have not incorporated
any other information by reference from our website, other than the documents listed below under the heading &#8220;<I>Incorporation of Certain Documents by Reference</I>.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> relating to the securities covered by this prospectus. This prospectus is a part of the registration statement and does not contain all the information in the registration statement. Whenever a reference
is made in this prospectus to a contract or other document of ours establishing the terms of the securities offered hereby, the reference is only a summary and you should refer to the exhibits that are a part of the registration statement for a copy
of the contract or other document. You may review a copy of the registration statement and the documents incorporated by reference herein through the SEC&#8217;s website listed above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_23"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus information contained in documents that we file with them,
which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically
update and supersede this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference in this prospectus the documents set forth below that have been
previously filed with the SEC as well as any filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of this offering; provided however, that we
are not incorporating any documents or information deemed to have been furnished rather than filed in accordance with SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000007/elv-20221231.htm">Form
 10-K</A>&nbsp;for the year ended December&nbsp;31, 2022, including the portions of our Definitive Proxy Statement on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000050/elv-20230331.htm">Schedule 14A</A>&nbsp;filed on March&nbsp;31, 2023 incorporated by reference into the Annual Report (except for Part I,
Item 1. &#8220;Business,&#8221; Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; Part II, Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; and Part IV, Item
15(c) &#8220;Financial Statement Schedule,&#8221; which have been recast in&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000109/elv-20230930_d2.htm">Exhibit 99.1</A>&nbsp;to our
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2023); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000054/elv-20230331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A>&nbsp;for the quarter ended March&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000088/elv-20230630.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A>&nbsp;for the quarter ended June&nbsp;30, 2023, as amended by Amendment No.&nbsp;1 to our Quarterly Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000102/elv-20230630.htm">Form 10-Q/A</A>; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000109/elv-20230930.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A>&nbsp;for the quarter ended September&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000119312523028419/d413102d8k.htm">February&nbsp;8,
 2023</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000119312523044107/d442834d8k.htm">February&nbsp;22, 2023</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000067/elv-20230510.htm">May&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000119312523205527/d492032d8k.htm">August&nbsp;
8, 2023</A> (other than Item 7.01 and the related Exhibit 99.1), and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1156039/000115603923000106/elv-20231004.htm">October&nbsp;5, 2023</A>; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1156039/000115603923000007/exhibit47-20221231forform1.htm">Exhibit
 4.7</A>&nbsp;to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, and any amendment or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information that we file with the SEC will automatically update and may replace information in this prospectus and information previously
filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge to each person, including any beneficial owner of the securities offered by this
prospectus, to whom this prospectus is delivered, upon written or oral request, a copy of any or all of the foregoing documents and any other documents that are incorporated by reference in this prospectus and the applicable prospectus supplement
(other than exhibits to such information, unless such exhibits are specifically incorporated by reference in such documents). Requests for such documents should be directed to our principal executive office at the following address: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Elevance Health, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220
Virginia Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Indianapolis, Indiana 46204 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone (833) <FONT STYLE="white-space:nowrap">401-1577</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not
authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information in this prospectus or any
prospectus supplement is accurate as of any date other than the date on the front of these documents. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_24"></A>OUR
COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Elevance Health, our purpose&#8212;to improve the health of humanity&#8212;is central to who we are. It inspires all we do
and is the driving force behind our unique approach to health. We know to meaningfully improve health, we must take a broader view. That is why our foundational approach looks at whole health and its most critical drivers: social, behavioral and
physical. We believe in working together to achieve our mission of improving lives and communities, simplifying healthcare and expecting more. We strive to deliver on our mission innovating, integrating and partnering to improve healthcare and
having a culture connected to our strategy. Our strategy is to become a lifetime, trusted health partner through the following four core focus areas: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Whole Health</I>&#8212;Partner to address physical, behavioral and social needs to improve health,
affordability, quality, equity and access for individuals and communities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exceptional Experiences</I><I></I>&#8212;Put the consumers we serve at the center of all that we do,
personalizing engagement to meet consumers where they are and optimize health outcomes across individuals and populations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Care Provider Enablement</I><I></I>&#8212;Be the easiest payer to work with by supporting care provider
partners with data, insights and tools they need to deliver exceptional care for our consumers. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Digital
Solutions</I><I></I>&#8212;Use digital technologies such as AI to transform the way we operate our business and interact with consumers by driving improvements in efficiency and experiences and converting data into actionable insights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Leadership</I><I></I><I>&#8212;</I>Redefine what is possible </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Community</I><I></I><I>&#8212;</I>Committed, connected, invested </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Integrity</I><I></I><I>&#8212;</I>Do the right thing, with a spirit of excellence </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Agility</I><I></I><I>&#8212;</I>Deliver today, transform tomorrow </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Diversity</I><I></I><I>&#8212;</I>Open our hearts and minds </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are one of the largest health insurers in the United States in terms of medical membership, serving over 47&nbsp;million medical members
through our affiliated health plans as of September&nbsp;30, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of
managed care services to <FONT STYLE="white-space:nowrap">fee-based</FONT> customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other
administrative services. We provide services to the federal government in connection with our Federal Health Products&nbsp;&amp; Services business, which administers the Federal Employees Health Benefits Program. We provide an array of specialty
services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an independent licensee of the Blue Cross and Blue Shield Association
(&#8220;BCBSA&#8221;), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (&#8220;BCBS&#8221;) licensee for Colorado, Connecticut, Georgia,
Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington,
D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup,
Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct
insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.&nbsp;Through various subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services,
Aspire Health, Carelon Behavioral Health and CareMore. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we announced in 2022, over the next several years we are organizing our brand
portfolio into the following core <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> brands: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield&#8212;represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wellpoint&#8212;we are uniting select <FONT STYLE="white-space:nowrap">non-BCBSA</FONT> licensed Medicare,
Medicaid and commercial plans under the Wellpoint name; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Carelon&#8212;this brand brings together our healthcare-related brands and capabilities, including our CarelonRx
and Carelon Services businesses, under a single brand name. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our branding strategy reflects the evolution of our
business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our
reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial&nbsp;&amp; Specialty Business and
Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate&nbsp;&amp; Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as
corporate expenses not allocated to our other reportable segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial&nbsp;&amp; Specialty Business, Government Business, CarelonRx and Other.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elevance Health is incorporated under the laws of the State of Indiana. Our principal executive offices are located at 220 Virginia
Avenue, Indianapolis, Indiana 46204 and our telephone number is (833) <FONT STYLE="white-space:nowrap">401-1577.</FONT> We maintain a website at<I><U>&nbsp;www.elevancehealth.com</U></I>&nbsp;where general information about us is available. We are
not incorporating the contents of the website into this prospectus or any prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to find more
information about us, please see the sections entitled &#8220;<I>Where You Can Find More Information&#8221;</I><I></I>&nbsp;and<I></I><I>&nbsp;&#8220;Incorporation of Certain Documents by Reference</I>&#8221; in this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_25"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves certain risks. Before acquiring any securities, you should carefully consider, among other things, the
matters discussed under &#8220;Risk Factors&#8221; in Item&nbsp;1A of our&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001156039/000115603923000007/elv-20221231.htm">Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December<U></U>&nbsp;31, 2022</A>, which are incorporated by reference herein, the risk factors described under the caption &#8220;Risk Factors&#8221; in any applicable prospectus supplement
and any risk factors set forth in our other filings with the SEC pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act before making an investment decision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_26"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, the net proceeds we receive from the sale of the securities offered by
this prospectus and the accompanying prospectus supplement will be used for general corporate purposes. General corporate purposes may include but are not limited to the repayment of debt, investments in or extensions of credit to our subsidiaries,
the financing of possible acquisitions or business expansion or the repurchase of shares of our common stock. The net proceeds may be invested temporarily or applied to repay short-term debt until they are used for their stated purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_27"></A>DESCRIPTION OF THE DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the
general terms and provisions of the indentures and the debt securities we may offer by this prospectus. The applicable prospectus supplement will describe the specific terms of the series of the debt securities then offered, and the terms and
provisions described in this section will apply only to the extent not superseded by the terms of the applicable prospectus supplement. Because this is only a summary, it does not contain all of the details found in the full text of the indentures
(as defined below) and the debt securities. We urge you to read carefully the full text of the indentures. The following summary is qualified in its entirety by the provisions of the indentures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities offered by this prospectus will be direct obligations of Elevance Health and will be either senior or subordinated debt,
which we refer to together as the debt securities. We will issue the debt securities under the senior note indenture dated as of November&nbsp;21, 2017 between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;senior
note indenture&#8221;), or the subordinated note indenture dated as of May&nbsp;12, 2015 between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;subordinated note indenture&#8221;). Senior debt will be issued under the
senior note indenture and subordinated debt will be issued under the subordinated note indenture. The senior note indenture and the subordinated note indenture are sometimes referred to in this prospectus individually as an &#8220;indenture&#8221;
and collectively as the &#8220;indentures.&#8221; The indentures have been qualified under the Trust Indenture Act of 1939. The indentures provide that our debt securities may be issued in one or more series, with different terms, in each case as
authorized from time to time by us. The indentures also give us the ability to reopen an existing series of debt securities and issue additional debt securities of that series or establish additional terms for that series of debt securities. None of
the indentures limits the amount of debt securities or other unsecured debt which we may issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the following description
of the debt securities, you should refer to the detailed provisions of each indenture, copies of which are filed as exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement will specify the specific terms of any issue of debt securities we may offer, including, where applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maximum aggregate principal amount, if any, established for debt securities of the series; provided, however,
that such amount may from time to time be increased by a board resolution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be senior or subordinated debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the debt securities will be sold; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the person to whom any interest on a debt security of the series will be payable, if other than the person in
whose name that debt security (or one or more predecessor debt securities) is registered at the close of business on the regular record date for such interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal and premium, if any, of any debt securities of the series will be
payable or the method used to determine or extend those dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates at which any debt securities of the series will bear interest, if any, or the method by which
such rate or rates shall be determined, the date or dates from which any such interest will accrue, or the method by which such date or dates shall be determined, the interest payment dates on which any such interest will be payable and the regular
record date, if any, for any such interest payable on any interest payment date, or the method by which such date or dates shall be determined, the basis upon which interest shall be calculated if other than that of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months, and the right, if any, to extend or defer interest payments and the duration of such extension or deferral; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, premium, if any, and interest on any debt securities of the series
will be payable, the place or places where the debt securities of such series may be presented for registration of transfer or exchange, the place or places where notices and demands to or upon us in respect of the debt securities of such series may
be made and the manner in which any payment may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which or the date or dates on which, the price or prices at which, the currency or
currency units in which, and the terms and conditions upon which any debt securities of the series may be redeemed, in whole or in part, at our option and, if other than by a board resolution, the manner in which any election by us to redeem the
debt securities will be evidenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our obligation or right, if any, to redeem or purchase any debt securities of the series pursuant to any sinking
fund, amortization or analogous provisions or at the option of the holder thereof and the period or periods within which, the price or prices at which, the currency or currency units in which, and the terms and conditions upon which any debt
securities of the series will be redeemed or purchased, in whole or in part, pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than denominations of $1,000 and any integral multiple thereof, the denominations in which any debt
securities of the series will be issuable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the trustee, the identity of each security registrar and/or paying agent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the amount of principal of, premium, if any, or interest on any debt securities of the series may be
determined with reference to a financial or economic measure or index or pursuant to a formula, the manner in which such amounts will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than U.S. dollars, the currency, currencies or currency units in which the principal of, premium, if
any, or interest on any debt securities of the series will be payable and the manner of determining the equivalent thereof in U.S. dollars for any purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the principal of, premium, if any, or interest on any debt securities of the series is to be payable, at our
election or the election of the holder thereof, in one or more currencies or currency units other than that or those in which such debt securities are stated to be payable, the currency, currencies or currency units in which the principal of,
premium, if any, or interest on such debt securities as to which such election is made will be payable, the periods within which or the dates on which and the terms and conditions upon which such election is to be made and the amount so payable (or
the manner in which such amount will be determined); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the provisions of the indenture relating to satisfaction and discharge thereof shall not apply to the debt
securities of that series as set forth therein, or if provisions for the satisfaction and discharge of the indenture other than as set forth therein shall apply to the debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the entire principal amount thereof, the portion of the principal amount of any debt securities of
the series which will be payable upon declaration of acceleration of the maturity thereof pursuant to the indenture or the method by which such portion shall be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the principal amount payable at the stated maturity of any debt securities of the series will not be
determinable as of any one or more dates prior to the stated maturity, the amount which will be deemed to be the principal amount of such debt securities as of any such date for any purpose thereunder or hereunder, including the principal amount
thereof which will be due and payable upon any maturity other than the stated maturity or which will be deemed to be outstanding as of any date prior to the stated maturity (or, in any such case, the manner in which such amount deemed to be the
principal amount will be determined); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than by a board resolution, the manner in which any election by us to defease any debt securities of the
series pursuant to the indenture will be evidenced; whether any debt securities of the series other than debt securities denominated in U.S. dollars and bearing interest at a fixed rate are to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
be subject to the defeasance provisions of the indenture; or, in the case of debt securities denominated in U.S. dollars and bearing interest at a fixed rate, if applicable, that the debt
securities of the series, in whole or any specified part, will not be defeasible pursuant to the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, that any debt securities of the series shall be issuable in whole or in part in the form of one or
more global securities and, in such case, the respective depositaries for such global securities, the form of any legend or legends which shall be borne by any such global security in addition to or in lieu of that set forth in the indenture and any
circumstances in which any such global security may be exchanged in whole or in part for debt securities registered, and any transfer of such global security in whole or in part may be registered, in the name or names of persons other than the
depositary for such global security or a nominee thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion from or change in the events of default applicable to any debt securities of the series
and any change in the right of the trustee or the requisite holders of such debt securities to declare the principal amount thereof due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion from or change in the covenants applicable to debt securities of the series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any right to convert or exchange debt securities of such series into any other securities or
property of ours or of any other corporation or person, and the additions or changes, if any, to the indenture with respect to the debt securities of such series to permit or facilitate such conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series will be guaranteed by any persons and, if so, the identity of such
persons, the terms and conditions upon which such debt securities will be guaranteed and, if applicable, the terms and conditions upon which such guarantees may be subordinated to other indebtedness of the respective guarantors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series will be secured by any collateral and, if so, the terms and conditions
upon which such debt securities will be secured and, if applicable, upon which such liens may be subordinated to other liens securing other indebtedness of us or of any guarantor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in a transaction registered under the Securities Act, and any
restriction or condition on the transferability of the debt securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued pursuant to a periodic offering program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exchanges, if any, on which the debt securities may be listed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities of the series (which terms will not be inconsistent with the provisions of
the applicable indenture, except as permitted thereunder). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement, the
senior debt securities will rank equally with all other unsecured and unsubordinated indebtedness of Elevance Health. The subordinated debt securities will rank subordinated and junior in right of payment, to the extent set forth in the subordinated
note indenture, to all Senior Debt, as defined herein, of Elevance Health. See &#8220;<I>Subordination</I>&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the debt
securities may be issued as discounted debt securities to be sold at a substantial discount below their stated principal amount. The prospectus supplement will contain any United States federal income tax consequences and other special
considerations applicable to discounted debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in a prospectus supplement, we will issue debt securities only as registered securities, which means that the name of
the holder will be entered in a register, which will be kept by the trustee or another agent of ours. Unless we state otherwise in a prospectus supplement, we will make principal and interest payments at the office of the paying agent or agents we
name in the prospectus supplement or by mailing a check to you at the address we have for you in the register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in a prospectus supplement, you will be able to transfer
registered debt securities at the office of the transfer agent or agents we name in the prospectus supplement. You may also exchange registered debt securities at the office of the transfer agent for an equal aggregate principal amount of registered
debt securities of the same series having the same maturity date, interest rate and other terms as long as the debt securities are issued in authorized denominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the trustee will impose any service charge for any transfer or exchange of a debt security; however, we may ask you to pay any
taxes or other governmental charges in connection with a transfer or exchange of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the debt securities are redeemable
and we redeem less than all of the debt securities of a particular series, we may block the transfer or exchange of debt securities during a specified period of time in order to freeze the list of holders to prepare the mailing. The period begins 15
days before the day we mail the notice of redemption and ends on the day of that mailing. We may also refuse to register transfers or exchanges of debt securities selected for redemption. However, we will continue to permit transfers and exchanges
of the unredeemed portion of any debt security being partially redeemed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Notes, Delivery and Form </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement, the debt securities will be issued in the form of one or more fully registered Global
Notes, as defined below, that will be deposited with, or on behalf of, The Depository Trust Company, referred to herein as the Depository, and registered in the name of the Depository&#8217;s nominee. A Global Note may be transferred, in whole and
not in part, only to another nominee of the Depository or to a successor of the Depository or its nominee. Global Notes are not exchangeable for definitive note certificates except in the specific circumstances described below. For purposes of this
prospectus, &#8220;<I>Global Note</I>&#8221; refers to the Global Note or Global Notes representing an entire issue of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depository has advised us as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Depository is: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited purpose trust company organized under the laws of the State of New York; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;banking organization&#8221; within the meaning of the New York banking law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing agency&#8221; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Depository was created to hold securities of its participants and to facilitate the clearance and settlement
of securities transactions among its participants through electronic book entry changes in accounts of its participants, eliminating the need for physical movements of securities certificates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Depository participants include securities brokers and dealers, banks, trust companies, clearing corporations
and others, some of whom own the Depository. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Access to the Depository book-entry system is also available to others that clear through or maintain a custodial
relationship with a participant, either directly or indirectly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Where we issue a Global Note in connection with the sale thereof to an underwriter or underwriters, the
Depository will immediately credit the accounts of participants designated by the underwriter or underwriters with the principal amount of the debt securities purchased by the underwriter or underwriters. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ownership of beneficial interests in a Global Note will be shown on, and the transfers of ownership will be
effected only through, records maintained by the Depository (with respect to participants), by the participants (with respect to indirect participants and certain beneficial owners) and by the indirect participants (with respect to all other
beneficial owners). The laws of some states require that certain </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
purchasers of securities take physical delivery in definitive form of securities they purchase. These laws may limit your ability to transfer beneficial interests in a Global Note.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as a nominee of the Depository is the registered owner of a Global Note, that nominee for all purposes will be
considered the sole owner or holder of the debt securities under the applicable indenture. Except as provided below, you will not be entitled to have debt securities registered in your name, will not receive or be entitled to receive physical
delivery of debt securities in definitive form, and will not be considered the owners or holders thereof under the applicable indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will make payment of principal of, premium, if any, and interest on debt securities represented by a Global Note to the Depository or its
nominee, as the case may be, as the registered owner and holder of the Global Note representing those debt securities. The Depository has advised us that upon receipt of any payment of principal of, or interest on, a Global Note, the Depository will
immediately credit accounts of participants with payments in amounts proportionate to their respective beneficial interests in the principal amount of that Global Note, as shown in the records of the Depository. Standing instructions and customary
practices will govern payments by participants to owners of beneficial interests in a Global Note held through those participants, as is now the case with securities held for the accounts of customers registered in &#8220;street name&#8221;. Those
payments will be the sole responsibility of those participants, subject to any statutory or regulatory requirements that may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, the trustee nor any of our respective agents will be responsible in any respect for actions or inactions of the Depository, any
nominee or any participant relating to, or payments made on account of, beneficial interests in a Global Note or for maintaining, supervising or reviewing any of the records of the Depository, any nominee or any participant relating to those
beneficial interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue debt securities in definitive form in exchange for a Global Note only in the following situations:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Depository is at any time unwilling or unable to continue as depository, and a successor depository is not
appointed by us within 120 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we choose to issue definitive debt securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if there is an Event of Default (as described herein), and there is a request from the Depository or any holder
of the debt securities to issue definitive debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any such instance, an owner of a beneficial interest in
a Global Note will be entitled to have debt securities equal in principal amount to that beneficial interest registered in its name and will be entitled to physical delivery of debt securities in definitive form. Debt securities in definitive form
will be issued in denominations of $1,000 and integral multiples thereof and will be issued in registered form only, without coupons. We will maintain one or more offices or agencies where debt securities may be presented for payment and may be
transferred or exchanged. You will not be charged a fee for any transfer or exchange of debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mergers and Similar Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
generally permitted to consolidate with or merge into any other person. In this section, &#8220;person&#8221; refers to any individual, corporation, partnership, limited liability company, joint venture, trust, unincorporated organization or
government or any agency or political subdivision of a government or governmental agency. We are also permitted to sell substantially all of our assets to any other person, or to buy substantially all of the assets of any other person. However, we
may not take any of these actions unless all the following conditions are met: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Where we merge out of existence or sell all or substantially all of our assets, the other person must be a
corporation (or the other person must include a corporate <FONT STYLE="white-space:nowrap">co-issuer</FONT> of the debt securities) organized under the laws of a state or the District of Columbia or under federal law and it must agree to be legally
responsible for the outstanding debt securities issued under the indentures. Upon assumption of our obligations by such a person in such circumstances, we shall be relieved of all obligations and covenants under the indentures and the debt
securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The merger, sale of all or substantially all of our assets or other transaction must not cause a default on the
debt securities, and we must not already be in default unless the merger or other transaction would cure the default. For purposes of this <FONT STYLE="white-space:nowrap">no-default</FONT> test, a default would include an Event of Default that has
occurred and not been cured, as described below under &#8220;Events of Default.&#8221; A default for this purpose would also include any event that would be an Event of Default if we received the required notice of our default or if under the
indentures the default would become an Event of Default after existing for a specified period of time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have delivered an officer&#8217;s certificate and an opinion of counsel to the trustee stating that the
transaction and any supplemental indenture required in connection therewith comply with the requirements of the applicable indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are three
types of changes we can make to the indentures and the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes Requiring Your Approval</I>. First, there are changes
that cannot be made to your debt securities without your specific approval. The following is a list of those types of changes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the stated maturity of the principal or interest on a debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce any amounts due on a debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce any premium payable upon the redemption of the debt securities or change the date on which any debt
securities may or must be redeemed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the place or currency of payment for a debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair your right to sue for payment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in principal amount of the debt securities, the approval of whose holders is needed to
modify or amend the applicable indenture or the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in principal amount of the debt securities, the approval of whose holders is needed to
waive compliance with certain provisions of the applicable indenture or to waive certain defaults; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify any other aspect of the provisions dealing with modification and waiver of the applicable indenture,
except to increase the percentage required for any modification or to provide that other provisions of such indenture may not be modified or waived without your consent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are convertible, make any change that adversely affects in any material respect the terms
of conversion of such debt securities unless such change is permitted by the terms of such debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes
Not Requiring Approval</I>. The second type of change does not require any vote by holders of the debt securities. This type is limited to corrections and clarifications and certain other changes that would not adversely affect holders of the debt
securities. The following is a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> list of those types of changes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidence the succession of another person to the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add to the covenants of the Company for the benefit of the holders of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add any additional Events of Default for the benefit of the holders of the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add one or more guarantees for the benefit of the holders of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint a successor trustee, or revise any provisions of the indentures necessary to administer the trusts under
the indentures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for the issuance of additional debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish the form or terms of any additional debt securities issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the rules of any applicable depository; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">alter any provisions of the indentures necessary to permit the issuance of debt securities in bearer form;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify any provisions regarding one or more series of the debt securities that affect only debt securities to be
issued under the applicable indenture after the changes take effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cure any ambiguity or mistakes in the indentures or the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any other provision under the indentures that does not adversely affect the interests of the holders of
the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supplement the indentures in order to permit the defeasance and discharge of any series of debt securities in any
manner that does not adversely affect the interest of the holders of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the rules or regulations of any securities exchange or automated quotation system on which the
debt securities may be listed or traded; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with SEC requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes Requiring a Majority Vote</I>. Any other change to the applicable indenture and the debt securities would require the following
approval: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects only debt securities of one series, it must be approved by the holders of not less than a
majority in principal amount of the debt securities of that series. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects the debt securities of one series as well as the debt securities of one or more other
series issued under the applicable indenture, it must be approved by the holders of not less than a majority in principal amount of the debt securities of each series affected by the change. In each case, the required approval must be given by
written consent. Most changes fall into this category. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same vote would be required for us to obtain a waiver of a
past default. However, we cannot obtain a waiver of a payment default or any other aspect of the applicable indenture or the debt securities listed in the first category described previously under &#8220;<I>Changes Requiring Your Approval</I>&#8221;
unless we obtain your individual consent to the waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Further Details Concerning Voting</I>. Debt securities will not be considered
outstanding, and therefore not eligible to vote, if we have deposited or set aside in trust for you money for their payment or redemption. Debt securities will also not be eligible to vote if they have been fully defeased as described later under
&#8220;<I>Defeasance&#8212;Full Defeasance</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will generally be entitled to set any day as a record date for the purpose of
determining the holders of outstanding debt securities that are entitled to vote or take other action under the applicable indenture. In certain limited circumstances, the trustee will be entitled to set a record date for action by holders. If we or
the trustee set a record date for a vote or other action to be taken by holders of debt securities, that vote or action may be taken only by persons who are holders of outstanding debt securities on the record date and must be taken within 180
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days following the record date or another period that we may specify (or as the trustee may specify, if it set the record date). We may shorten or lengthen (but not beyond 180 days) this period
from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion and Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of any series may be convertible into or exchangeable for other securities of Elevance Health or another issuer or property
or cash on the terms and subject to the conditions set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, the prospectus
supplement will specify: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type of securities into which the debt security may be converted or exchanged; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion price or exchange ratio, and its method of calculation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether conversion or exchange is mandatory or at your election; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how the conversion price or exchange ratio may be adjusted if our debt securities are redeemed.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures include provisions allowing defeasance of the debt securities, which means that we may discharge our entire indebtedness under the indentures, if specific acts are performed. The indentures provide for full defeasance and covenant
defeasance, as further described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Full Defeasance</I>. If there is a change in U.S. federal tax law, as described below, we can
legally release ourselves from any payment or other obligations on the debt securities, which we refer to as a full defeasance, if we put in place the following other arrangements for you to be repaid: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of
the same series money or U.S. government or U.S. government agency notes or bonds, or a combination thereof, that will generate enough cash to make interest, principal, any premium and any other payments on the debt securities of that series on
their various due dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There must be a change in current U.S. federal tax law or an Internal Revenue Service ruling that lets us make
the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. Under current U.S. federal tax law, the deposit and our legal
release from the debt securities would be treated as though we took back your debt securities and gave you your share of the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities
you give back to us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deliver to the trustee a legal opinion of our counsel confirming the tax law change described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we ever did accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for
repayment of the debt securities. You could not look to us for repayment in the event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever become bankrupt or
insolvent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the subordinated note indenture provides that if we choose to have the defeasance and discharge provision applied
to the subordinated debt securities, the subordination provisions of the subordinated note indenture will become ineffective upon full defeasance of the subordinated debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, even if we make the deposit in trust and opinion delivery arrangements discussed above, a number of our obligations relating to the
debt securities will remain. These include our obligations: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to register the transfer and exchange of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to replace mutilated, destroyed, lost or stolen debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to maintain paying agencies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to hold money for payment in trust. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance</I>. Under current U.S. federal tax law, we can make the same type of deposit described above and be released from some
of the covenants in the debt securities, which we refer to as covenant defeasance. In that event, you would lose the protection of those covenants but would gain the protection of having money and securities set aside in trust to repay the debt
securities. In order to achieve covenant defeasance, we must do the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of
the same series money or U.S. government or U.S. government agency notes or bonds, or a combination thereof, that will generate enough cash to make interest, principal, any premium and any other payments on the debt securities of that series on
their various due dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income
tax law we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we accomplish covenant defeasance, you can still look to us for repayment of the debt securities if there were a shortfall in the trust
deposit. In fact, if one of the Events of Default occurred (such as our bankruptcy) and the debt securities become immediately due and payable, there may be such a shortfall. Depending on the event causing the default, you may not be able to obtain
payment of the shortfall. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Satisfaction and Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures will cease to be of further effect and the trustee, upon our demand and at our expense, will execute appropriate instruments
acknowledging the satisfaction and discharge of the applicable indenture upon compliance with certain conditions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our having paid all sums payable by us under the applicable indenture, as and when the same shall be due and
payable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our having delivered to the trustee for cancellation all debt securities theretofore authenticated under the
applicable indenture; or, all debt securities of any series outstanding under the applicable indenture not theretofore delivered to the trustee for cancellation shall have become due and payable or are by their terms to become due and payable within
one year and we shall have deposited with the trustee sufficient cash or U.S. government or U.S. government agency notes or bonds that will generate enough cash to pay, at maturity or upon redemption, all such debt securities of any series
outstanding under the applicable indenture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our having delivered to the trustee an officer&#8217;s certificate and an opinion of counsel, each stating that
these conditions have been satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Highly Leveraged Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general provisions of the indentures do not afford holders of the debt securities protection in the event of a highly leveraged or other
transaction involving us that may adversely affect holders of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any subordinated debt securities issued under the subordinated note indenture will be subordinate and junior in right of payment to all of our
Senior Debt (including all debt securities issued under the senior note </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indenture) whether existing at the date of the subordinated note indenture or subsequently incurred. Upon any payment or distribution of our assets to creditors upon any: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dissolution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">winding-up;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receivership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reorganization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assignment for the benefit of creditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marshaling of assets and liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insolvency; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt restructuring or similar proceedings in connection with any insolvency or bankruptcy proceeding,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the holders of Senior Debt will first be entitled to receive payment in full of the principal of, premium, if any, and interest on such
Senior Debt before the holders of the subordinated debt securities will be entitled to receive or retain any payment in respect of the principal of, premium, if any, or interest on the subordinated debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the acceleration of the maturity of any subordinated debt securities, the holders of all Senior Debt outstanding at the time of the
acceleration will first be entitled to receive payment in full of all amounts due thereon, including any amounts due upon acceleration, before the holders of subordinated debt securities will be entitled to receive or retain any payment in respect
of the principal of, premium, if any, or interest on the subordinated debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No payments on account of principal, or any
premium or interest, in respect of the subordinated debt securities may be made if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there has occurred and is continuing a default in any payment with respect to Senior Debt; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there has occurred and is continuing an Event of Default with respect to any Senior Debt resulting in the
acceleration of, or permitting the holder or holders thereof to accelerate, the maturity thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Senior
Debt&#8221; means the principal of, and any premium and interest (including interest accruing on or after the filing of any petition in bankruptcy or for reorganization relating to us, whether or not such claim for post-petition interest is allowed
in such proceeding) on our Debt, whether incurred on, before or after the date of the subordinated note indenture, unless the instrument creating or evidencing the Debt or under which the Debt is outstanding provides that obligations created by it
are not superior in right of payment to the subordinated debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Debt&#8221; means, with respect to any person, whether
recourse is to all or a portion of the assets of that person and whether or not contingent: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every obligation of that person for money borrowed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every obligation of that person evidenced by bonds, debentures, notes or other similar instruments, including
obligations incurred in connection with the acquisition of property, assets or businesses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every reimbursement obligation of that person with respect to letters of credit, bankers&#8217; acceptances or
similar facilities issued for the account of that person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every obligation of that person incurred in connection with the acquisition of property or services, but
excluding trade accounts payable or accrued liabilities arising in the ordinary course of business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every capital lease obligation of that person; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">every obligation of the type referred to above of another person and all dividends of another person the payment
of which, in either case, such person has guaranteed or for which such person is responsible or liable, directly or indirectly, as obligor or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures will place no limitation on the amount of additional Senior Debt that we may incur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture defines
an Event of Default with respect to any series of debt securities. Unless otherwise provided in the applicable prospectus supplement, Events of Default are any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not pay the principal or any premium on a note on its due date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not pay interest on a note within 30 days of its due date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not make any sinking fund payment when due. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We remain in breach of any other term of the applicable indenture for 90 days after we receive a notice of
default stating we are in breach. The notice must be sent by either the trustee or holders of 25% of the principal amount of the debt securities of the affected series. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We file for bankruptcy or certain other events in bankruptcy, insolvency or reorganization occur.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Event of Default under one series of debt securities does not necessarily constitute an Event of Default under any
other series of debt securities. Each indenture provides that the trustee may withhold notice to the holders of any series of debt securities issued thereunder of any default if the trustee considers it in the interest of such holders to do so
provided the trustee may not withhold notice of default in the payment of principal, premium, if any, or interest, if any, on any of the debt securities of that series or in the making of any sinking fund installment or analogous obligation with
respect to that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Remedies If an Event of Default Occurs</I>. Each indenture provides that if an Event of Default has occurred
and has not been cured, the trustee or the holders of 25% in principal amount of the debt securities of the affected series may declare the entire principal amount of all the debt securities of that series to be due and immediately payable. This is
called a declaration of acceleration of maturity. If an Event of Default occurs because of certain events in bankruptcy, insolvency or reorganization, the principal amount of all the debt securities will be automatically accelerated, without any
action by the trustee or any holder. A declaration of acceleration of maturity may be cancelled by the holders of at least a majority in principal amount of the debt securities of the affected series if certain conditions are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of any series may waive the rights of all holders with
respect to past defaults. Holders of a majority in principal amount of the outstanding debt securities, however, may not waive the rights of all holders relating to these events if they involve a default in payment obligations or a provision of the
applicable indenture that cannot be modified or amended without the consent of each holder of debt securities of such series affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may otherwise be provided in the indentures in cases of default, where the trustee has some special duties, the trustee is not
required to take any action under the applicable indenture at the request of any holders unless the holders offer the trustee reasonable protection from expenses and liability, which is called an indemnity. If a reasonable indemnity is provided, the
holders of a majority in principal amount of the debt securities outstanding of the affected series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. Subject to
certain exceptions contained in the indentures, these majority holders may also direct the trustee in performing any other action under the applicable indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before you bypass the trustee and bring your own lawsuit or other formal legal action or
take other steps to enforce your rights or protect your interests relating to the debt securities, the following must occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You must give the trustee written notice that an Event of Default has occurred and remains uncured.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The holders of 25% in principal amount of all outstanding debt securities of the affected series must make a
written request that the trustee take action because of the Event of Default, and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No inconsistent written requests by holders of a majority in principal amount of all outstanding debt securities
of the affected series have been made to the trustee within the 60 days after the written notice of the Event of Default is sent to the trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, you are entitled at any time to bring a lawsuit for the payment of money due on your debt security on or after the due date of that
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish to the trustee every year a written statement of one of our officers certifying that to such officer&#8217;s
knowledge we are in compliance with the indentures and the debt securities, or else specifying any default. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the Trust Indenture Act of 1939 applies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon Trust Company, N.A. is the trustee under the indentures. The Bank of New York Mellon Trust Company, N.A. is the
trustee under those certain indentures pursuant to which each of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.350% senior unsecured notes due 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.500% senior unsecured notes due 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 2.375% senior unsecured notes due 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.350% senior unsecured notes due 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 1.500% senior unsecured notes due 2026; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.900% senior unsecured notes due 2026; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.650% senior unsecured notes due 2027; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.101% senior unsecured notes due 2028; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 2.875% senior unsecured notes due 2029; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 2.250% senior unsecured notes due 2030; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 2.550% senior unsecured notes due 2031; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.100% senior unsecured notes due 2032; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.500% senior unsecured notes due 2032; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.750% senior unsecured notes due 2033; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.950% senior unsecured notes due 2034; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.850% senior unsecured notes due 2036; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 6.375% senior unsecured notes due 2037; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.800% senior unsecured notes due 2040; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.625% senior unsecured notes due 2042; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.650% senior unsecured notes due 2043; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.100% senior unsecured notes due 2044; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.650% senior unsecured notes due 2044; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.375% senior unsecured notes due 2047; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.550% senior unsecured notes due 2048; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.700% senior unsecured notes due 2049; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.125% senior unsecured notes due 2050; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 3.600% senior unsecured notes due 2051; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.550% senior unsecured notes due 2052; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 6.100% senior unsecured notes due 2052; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 5.125% senior unsecured notes due 2053; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Elevance Health&#8217;s 4.850% senior unsecured notes due 2054 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are outstanding. The Bank of New York Mellon Trust Company, N.A. also is the fiscal agent under the fiscal agency agreement pursuant to which Anthem Insurance
Companies, Inc.&#8217;s 9.000% surplus notes due 2027 are outstanding. The Bank of New York Mellon Corporation, an affiliate of the trustee, also performs services for us in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_28"></A>DESCRIPTION OF THE PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the general terms and provisions of the preferred stock we may offer by this prospectus. The applicable prospectus
supplement will describe the specific terms of the series of the preferred stock then offered, and the terms and provisions described in this section will apply only to the extent not superseded by the terms of the applicable prospectus supplement.
Because this is only a summary, it does not contain all of the terms applicable to the preferred stock that we may offer. We urge you to read carefully our amended and restated articles of incorporation, as amended (our &#8220;articles of
incorporation&#8221;), and the articles of amendment we have filed or will file in relation to an issue of any particular series of preferred stock before you buy any preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 100,000,000 shares of preferred stock, without par value, none of which is issued or outstanding. Our board
of directors may issue from time to time shares of preferred stock in one or more series and with the relative powers, rights and preferences and for the consideration our board of directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may, without further action of the shareholders, determine and set forth in an amendment to our articles of
incorporation the following for each series of preferred stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the serial designation and the number of shares in that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate or rates, whether dividends shall be cumulative and, if so, from what date, the payment date or
dates for dividends, and any rights of priority or participating or other special rights with respect to dividends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any voting rights of the shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the shares will be redeemable or convertible and, if so, the price or prices at which, and the terms and
conditions on which the shares may be redeemed or converted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount or amounts payable upon the shares in the event of voluntary or involuntary liquidation, dissolution
or winding up of us prior to any payment or distribution of our assets to any class or classes of our stock ranking junior to the preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the shares will be entitled to the benefit of a sinking fund and, if so entitled, the amount of the fund
and the manner of its application, including the price or prices at which the shares may be redeemed or purchased through the application of the fund; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the shares will be subject to any restrictions on the issue of additional shares in addition to those
restrictions already provided for in our articles of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other preferences, privileges and powers, and relative, participating, optional, or other special rights, and
qualifications, limitations or restrictions, as our board of directors may deem advisable and as shall not be inconsistent with the provisions of our articles of incorporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the rights prescribed for a series of preferred stock, the issuance of preferred stock could have an adverse effect on the voting
power of the holders of common stock or could impose restrictions upon the payment of dividends and other distributions to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock, when issued, will be fully paid and nonassessable. Unless the applicable prospectus supplement provides otherwise, the
preferred stock will have no preemptive rights to subscribe for any additional securities which may be issued by us in the future. The transfer agent and registrar for the preferred stock will be specified in the applicable prospectus supplement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_29"></A>DESCRIPTION OF THE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the general terms and provisions of our common stock. For additional information regarding our common stock,
please refer to our articles of incorporation, our bylaws, as amended (&#8220;bylaws&#8221;) and the applicable provisions of the Indiana Business Corporation Law, as amended (the &#8220;IBCL&#8221;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to
900,000,000 shares of common stock, par value $0.01 per share. Each holder of our common stock is entitled to one vote per share of record on all matters to be voted upon by the shareholders. Holders do not have cumulative voting rights in the
election of directors or any other matter. Subject to the preferential rights of the holders of any preferred stock that may at the time be outstanding, each share of common stock will entitle the holder of that share to an equal and ratable right
to receive dividends or other distributions (other than purchases, redemptions or other acquisitions of shares by us) if declared from time to time by our board of directors and if there are sufficient funds to legally pay a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, whether voluntary or involuntary, the holders of common stock will be entitled to
share ratably in all assets remaining after payments to creditors and after satisfaction of the liquidation preference, if any, of the holders of any preferred stock that may at the time be outstanding. Holders of common stock have no preemptive or
redemption rights and will not be subject to further calls or assessments by us. Any shares of common stock offered by this prospectus will, when issued, be fully paid and nonassessable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized But Unissued Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IBCL
does not require shareholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate
corporate acquisitions. One of the effects of the existence of authorized but unissued shares may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage
an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of current management and possibly deprive the shareholders of opportunities to sell their shares of common stock
at prices higher than prevailing market prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Ownership of Our Common Stock in Articles of Incorporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required under our licenses with the Blue Cross and Blue Shield Association (&#8220;BCBSA&#8221;), our articles of incorporation contain
certain limitations on the ownership of our common stock. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock in excess of specified ownership limits, except with the prior approval of a majority
of the &#8220;continuing directors.&#8221; The ownership limits, which may not be exceeded without the prior approval of the BCBSA, are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any institutional investor (as defined in our articles of incorporation), one share less than 10% of our
outstanding voting securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any <FONT STYLE="white-space:nowrap">non-institutional</FONT> investor (as defined in our articles of
incorporation), one share less than 5% of our outstanding voting securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any person, one share less than the number of shares of our common stock or other equity securities (or a
combination thereof) representing a 20% ownership interest in us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any transfer of stock that would result in any person
beneficially owning shares of capital stock in excess of any ownership limit will result in the intended transferee acquiring no rights in the shares exceeding such ownership limit (with certain exceptions) and the person&#8217;s excess shares will
be deemed transferred to an escrow agent to be held until the shares are transferred to a person whose ownership of the shares will not violate the ownership limit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Other Provisions of Our Articles of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain other provisions of our articles of incorporation and bylaws may delay or make more difficult unsolicited acquisitions or changes of
control of us. These provisions could have the effect of discouraging third parties from making proposals involving an unsolicited acquisition or change in control of us, although these proposals, if made, might be considered desirable by a majority
of our shareholders. These provisions may also have the effect of making it more difficult for third parties to cause the replacement of the current management without the concurrence of the board of directors. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the division of the board of directors into three classes serving staggered terms of office of three years;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions limiting the maximum number of directors to 19 and requiring that any increase in the number of
directors then in effect must be approved by a majority of continuing directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions requiring that, except in certain limited circumstances, the filling of any vacancy on the board of
directors must be approved by a majority of continuing directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permitting a special meeting of shareholders to be called only by the board of directors, the Chair of the Board,
the Lead Director, the Chief Executive Officer, the President, or upon the written demand of any one or more shareholders owning at least 20% of our outstanding common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements for advance notice for raising business or making nominations at shareholders&#8217; meetings.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws provide that if the requirement for a classified board structure set forth in our licenses with the BCBSA is
eliminated or otherwise no longer applicable to the Company, the board of directors will take all necessary actions to implement the elimination of the classified board structure and the annual election of all directors, which shall be phased in
over a three-year period commencing with the first annual meeting of shareholders occurring at least 90 days after the board of directors determines that such requirement is eliminated or is otherwise no longer applicable to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws establish an advance notice procedure with regard to business to be brought before an annual or special meeting of shareholders and
advance notice and proxy access procedures with regard to the nomination of candidates for election as directors, other than by or at the direction of the&nbsp;board of directors, including nominations made in accordance with Rule <FONT
STYLE="white-space:nowrap">14a-19</FONT> promulgated under the Exchange Act. Although our bylaws do not give the board of directors any power to approve or disapprove shareholder nominations for the election of directors or proposals for action,
they may have the effect of precluding a contest for the election of directors or the consideration of shareholder proposals if the established procedures are not followed, and of discouraging or deterring a third party from conducting a
solicitation of proxies to elect its own slate of directors or to approve its proposal without regard to whether consideration of those nominees or proposals might be harmful or beneficial to us and our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for
(a)&nbsp;any derivative action or proceeding brought on our behalf, (b)&nbsp;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or certain specified constituents of ours,
(c)&nbsp;any action asserting a claim arising pursuant to any provision of the IBCL or our articles of incorporation or bylaws, or (d)&nbsp;any action asserting a claim governed by the internal affairs doctrine, will be, to the fullest extent
permitted by law, the Marion Superior Court in Marion County, Indiana or, if the Marion Superior Court lacks jurisdiction, the United States District Court for the Southern District of Indiana. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Provisions of the Indiana Business Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an Indiana corporation, we are governed by the IBCL. The following are some of the more significant provisions of the IBCL that may delay,
prevent or make more difficult certain unsolicited acquisitions or changes of control of us. These provisions also may have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to
accomplish transactions which shareholders may otherwise deem to be in their best interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Control Share Acquisitions.</I>&nbsp;Under Chapter 42 of the IBCL, an acquiring person or
group who acquires, directly or indirectly, ownership of, or the power to direct the exercise of voting power with respect to, issued and outstanding &#8220;control shares&#8221; in an &#8220;issuing public corporation&#8221; may not exercise voting
rights on any control shares unless these voting rights are conferred by a majority vote of the disinterested shareholders of the issuing public corporation at a special meeting of those shareholders held upon the request and at the expense of the
acquiring person or, if no such request is made, at the next special or annual meeting of shareholders. If the acquiring person has acquired control shares with a majority or more of the voting power, and the control shares are accorded full voting
rights by the disinterested shareholders, all shareholders of the issuing public corporation have dissenters&#8217; rights to receive the fair value of their shares pursuant to Chapter 44 of the IBCL. We are an &#8220;issuing public
corporation&#8221; as defined under Chapter 42. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Chapter 42, &#8220;control shares&#8221; means shares acquired by a person that,
when added to all other shares of the issuing public corporation owned by that person or in respect to which that person may exercise or direct the exercise of voting power, would otherwise entitle that person to exercise voting power of the issuing
public corporation in the election of directors within any of the following ranges: <FONT STYLE="white-space:nowrap">(i)&nbsp;one-fifth</FONT> or more but less than <FONT STYLE="white-space:nowrap">one-third;</FONT>
<FONT STYLE="white-space:nowrap">(ii)&nbsp;one-third</FONT> or more but less than a majority; or (iii)&nbsp;a majority or more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chapter
42 does not apply if, before a control share acquisition is made, the corporation&#8217;s articles of incorporation or bylaws, including a bylaw adopted by the corporation&#8217;s board of directors, provide that such chapter does not apply. Our
bylaws provide that we are not subject to Chapter 42; however, our board of directors could amend our bylaws to rescind our election to opt out of Chapter 42. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Business Combinations.</I>&nbsp;Chapter 43 of the IBCL restricts the ability of an Indiana corporation that has 100 or more
shareholders to engage in any business combinations with an &#8220;interested shareholder&#8221; for five years after the date the shareholder became an &#8220;interested shareholder&#8221; (such date, the &#8220;share acquisition date&#8221;),
unless the business combination or the purchase of shares by the interested shareholder on the interested shareholder&#8217;s share acquisition date is approved by the board of directors of the corporation before the share acquisition date. If such
prior approval is not obtained, the interested shareholder may effect a business combination after the five-year period only if that shareholder receives approval from a majority of the disinterested shareholders or the offer meets specified fair
price criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Chapter 43, &#8220;interested shareholder&#8221; means any person, other than the corporation or its
subsidiaries, who is (1)&nbsp;the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation or (2)&nbsp;an affiliate or associate of the corporation, which at any time within the
five-year period immediately before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding shares of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chapter 43 does not apply to corporations that elect not to be subject to Chapter 43 in an amendment to their articles of incorporation
approved by a majority of the disinterested shareholders. That amendment, however, cannot become effective until 18 months after its passage and would apply only to share acquisitions occurring after its effective date. Our articles of incorporation
do not exclude us from Chapter 43. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Classified Board of Directors</I>. Under Chapter 33 of the IBCL, a corporation with a
class of voting shares registered with the SEC under Section&nbsp;12 of the Exchange Act must have a classified board of directors unless the corporation adopts a bylaw expressly electing not to be governed by this provision. Although our articles
of incorporation and bylaws provide for a classified board of directors so long as we are required to do so under our licenses with the BCBSA, we adopted an amendment to our bylaws electing not to be subject to this mandatory requirement effective
July&nbsp;29, 2009. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unanimous Written Consent of Shareholders</I>. Under Chapter 29 of the IBCL, as well as our articles of
incorporation and our bylaws, any action required or permitted to be taken by the holders of common stock may be effected only at an annual meeting or special meeting of such holders, and shareholders may act in lieu of such meetings only by
unanimous written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Repeal of Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles of incorporation and bylaws provide that the bylaws may be altered, amended or repealed by either (1)&nbsp;the affirmative vote of
a majority of the entire number of directors, or (2)&nbsp;except for certain provisions of the bylaws, the affirmative vote, at a shareholder meeting, of at least a majority of the votes entitled to be cast by the holders of the outstanding shares
of all classes of our stock entitled to vote generally in the election of directors, considered for this purpose as a single voting group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock trades on the New York Stock Exchange under the symbol &#8220;ELV.&#8221; Computershare Trust Company, N.A. is the
registrar, transfer agent, conversion agent and dividend disbursing agent for the common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_30"></A>DESCRIPTION OF THE DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue receipts for
depositary shares, each of which will represent a fractional interest of a share of a particular series of preferred stock, as specified in the applicable prospectus supplement. We will deposit shares of preferred stock represented by depositary
shares under a separate deposit agreement among us, a preferred stock depositary and the holders from time to time of the depositary shares. Subject to the terms of the applicable deposit agreement, each owner of a depositary receipt will be
entitled, in proportion to the fractional interest of a share of a particular series of preferred stock represented by the depositary shares evidenced by such depositary receipt, to all the rights and preferences of the preferred stock represented
by such depositary shares (including dividend, voting, conversion, redemption and liquidation rights). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shares will be
evidenced by depositary receipts issued pursuant to the applicable deposit agreement. Immediately following the issuance and delivery of the shares of preferred stock by us to a preferred stock depositary, we will cause such preferred stock
depositary to issue, on our behalf, the depositary receipts. Copies of the applicable form of deposit agreement and depositary receipt may be obtained from us upon request, and the statements made hereunder relating to the deposit agreement and the
depositary receipts to be issued thereunder are summaries of certain provisions thereof and do not purport to be complete and are subject to, and qualified in their entirety by reference to, all of the provisions of the applicable deposit agreement
and related depositary receipts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock depositary will distribute all cash dividends or other cash distributions received in respect of the shares of preferred
stock to the record holders of depositary receipts evidencing the related depositary shares in proportion to the number of such depositary receipts owned by such holders, subject to certain obligations of holders to file proofs, certificates and
other information and to pay certain charges and expenses to the preferred stock depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a distribution other than in
cash, the preferred stock depositary will distribute property received by it to the record holders of depositary receipts entitled thereto, subject to certain obligations of holders to file proofs, certificates and other information and to pay
certain charges and expenses to the preferred stock depositary, unless the preferred stock depositary determines that it is not feasible to make such distribution, in which case the preferred stock depositary may, with our approval, sell such
property and distribute the net proceeds from such sale to such holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No distribution will be made in respect of any depositary share
to the extent that it represents any shares of preferred stock converted into other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender of the depositary receipts at the corporate trust office of the applicable preferred stock depositary (unless the related
depositary shares have previously been called for redemption or converted into other securities), the holders thereof will be entitled to delivery at such office, to or upon such holder&#8217;s order, of the number of whole or fractional shares of
preferred stock and any money or other property represented by the depositary shares evidenced by such depositary receipts. Holders of depositary receipts will be entitled to receive whole or fractional shares of preferred stock on the basis of the
proportion of shares of preferred stock represented by each depositary share as specified in the applicable prospectus supplement, but holders of such shares of preferred stock will not thereafter be entitled to receive depositary shares therefor.
If the depositary receipts delivered by the holder evidence a number of depositary shares in excess of the number of depositary shares representing the number of shares of preferred stock to be withdrawn, the preferred stock depositary will deliver
to such holder at the same time a new depositary receipt evidencing such excess number of depositary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we redeem shares of preferred stock held by the preferred stock depositary, the preferred stock depositary will redeem as of the same
redemption date the number of depositary shares representing shares of preferred stock so redeemed, provided we shall have paid in full to the preferred stock depositary the redemption price of the shares of preferred stock to be redeemed plus an
amount equal to any accrued and unpaid dividends thereon to the date fixed for redemption. The redemption price per depositary share will be equal to the corresponding proportion of the redemption price and any other amounts per share payable with
respect to the shares of preferred stock. If fewer than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected pro rata (as nearly as may be practicable without creating fractional depositary shares) or
by any other equitable method determined by us that will not result in a violation of the ownership restrictions in our charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and
after the date fixed for redemption, all dividends in respect of the shares of preferred stock so called for redemption will cease to accrue, the depositary shares so called for redemption will no longer be deemed to be outstanding and all rights of
the holders of the depositary receipts evidencing the depositary shares so called for redemption will cease, except the right to receive any moneys payable upon such redemption and any money or other property to which the holders of such depositary
receipts were entitled upon such redemption and surrender thereof to the preferred stock depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting of the Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting at which the holders of the applicable shares of preferred stock are entitled to vote, the preferred
stock depositary will mail the information contained in such notice of meeting to the record holders of the depositary receipts evidencing the depositary shares which represent such shares of preferred stock. Each record holder of depositary
receipts evidencing depositary shares on the record date (which will be the same date as the record date for the shares of preferred stock) will be entitled to instruct the preferred stock depositary as to the exercise of the voting rights
pertaining to the amount of shares of preferred stock represented by such holder&#8217;s depositary shares. The preferred stock depositary will vote the amount of shares of preferred stock represented by such depositary shares in accordance with
such instructions, and we will agree to take all reasonable action which may be deemed necessary by the preferred stock depositary in order to enable the preferred stock depositary to do so. The preferred stock depositary will abstain from voting
the amount of shares of preferred stock represented by such depositary shares to the extent it does not receive specific instructions from the holders of depositary receipts evidencing such depositary shares. The preferred stock depositary shall not
be responsible for any failure to carry out any instruction to vote, or for the manner or effect of any such vote made, as long as any such action or <FONT STYLE="white-space:nowrap">non-action</FONT> is in good faith and does not result from
negligence or willful misconduct of the preferred stock depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, whether voluntary or involuntary, the holders of each depositary receipt will be
entitled to the fraction of the liquidation preference accorded each share of preferred stock represented by the depositary shares evidenced by such depositary receipt, as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion of Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary shares, as such, are not convertible into common stock or any of our other securities or property. Nevertheless, if so specified in the applicable prospectus supplement relating to an offering of depositary shares, the depositary receipts
may be surrendered by holders thereof to the preferred stock depositary with written instructions to the preferred stock depositary to instruct us to cause conversion of the shares of preferred stock represented by the depositary shares evidenced by
such depositary receipts into whole shares of common stock or other shares of preferred stock, and we agree that upon receipt of such instructions and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amounts payable in respect thereof, we will cause the conversion thereof utilizing the same procedures as those provided for delivery of shares of preferred stock to effect such conversion. If
the depositary shares evidenced by a depositary receipt are to be converted in part only, a new depositary receipt or receipts will be issued for any depositary shares not to be converted. No fractional shares of common stock will be issued upon
conversion, and if such conversion would result in a fractional share being issued, an amount will be paid in cash by us equal to the value of the fractional interest based upon the closing price of the common stock on the last business day prior to
the conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of a Deposit Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares which represent the preferred stock and any provision of the deposit agreement
may at any time be amended by agreement between us and the preferred stock depositary. However, any amendment that materially and adversely alters the rights of the holders of depositary receipts, or that would be materially and adversely
inconsistent with the rights granted to the holders of the related shares of preferred stock, will not be effective unless such amendment has been approved by the existing holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
applicable depositary shares evidenced by the applicable depositary receipts then outstanding. No amendment shall impair the right, subject to certain exceptions in the deposit agreement, of any holder of depositary receipts to surrender any
depositary receipt with instructions to deliver to the holder the related shares of preferred stock and all money and other property, if any, represented thereby, except in order to comply with law. Every holder of an outstanding depositary receipt
at the time any such amendment becomes effective shall be deemed, by continuing to hold such receipt, to consent and agree to such amendment and to be bound by the deposit agreement as amended thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may be terminated by us upon not less than 30&nbsp;days&#8217; prior written notice to the preferred stock depositary if
a&nbsp;majority of each series of preferred stock affected by such termination consents to such termination, whereupon the preferred stock depositary shall deliver or make available to each holder of depositary receipts, upon surrender of the
depositary receipts held by such holder, such number of whole or fractional shares of preferred stock as are represented by the depositary shares evidenced by such depositary receipts together with any other property held by the preferred stock
depositary with respect to such depositary receipts. In addition, the deposit agreement will automatically terminate if (a)&nbsp;all outstanding depositary shares shall have been redeemed, (b)&nbsp;there shall have been a final distribution in
respect of the related shares of preferred stock in connection with our liquidation, dissolution or winding up and such distribution shall have been distributed to the holders of depositary receipts evidencing the depositary shares representing such
shares of preferred stock or (c)&nbsp;each related share of preferred stock shall have been converted into our securities not so represented by depositary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of a Preferred Stock Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the deposit agreement. In addition, we
will pay the fees and expenses of the preferred stock depositary in connection with the performance of its duties under the deposit agreement. However, holders of depositary receipts will pay the fees and expenses of the preferred stock depositary
for any duties requested by such holders to be performed which are outside of those expressly provided for in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and
Removal of Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock depositary may resign at any time by delivering to us notice of its election to do so, and
we may at any time remove the preferred stock depositary, any such resignation or removal to take effect upon the appointment of a successor preferred stock depositary. A successor preferred stock depositary must be appointed within 60&nbsp;days
after delivery of the notice of resignation or removal and must be a bank or trust company having its principal office in the United States and that meets certain combined capital and surplus requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miscellaneous </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock depositary will forward to holders of depositary receipts any reports and communications from us which are received by the
preferred stock depositary with respect to the related shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the preferred stock depositary will be
liable if it is prevented from or delayed in, by law or any circumstances beyond its control, performing its obligations under the deposit agreement. The obligations of us and the preferred stock depositary under the deposit agreement will be
limited to performing their duties thereunder in good faith and without negligence (in the case of any action or inaction in the voting of shares of preferred stock represented by the depositary shares), gross negligence or willful misconduct, and
we and the preferred stock depositary will not be obligated to prosecute or defend any legal proceeding in respect of any depositary receipts, depositary shares or shares of preferred stock represented thereby unless satisfactory indemnity is
furnished. We and the preferred stock depositary may rely on written advice of counsel or accountants, or information provided by persons presenting shares of preferred stock represented thereby for deposit, holders of depositary receipts or other
persons believed in good faith to be competent to give such information, and on documents believed in good faith to be genuine and signed by a proper party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the preferred stock depositary shall receive conflicting claims, requests or instructions from any holders of depositary
receipts, on the one hand, and us, on the other hand, the preferred stock depositary shall be entitled to act on such claims, requests or instructions received from us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement
will identify the depositary for the depositary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of the Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will specify whether or not the depositary shares will be listed on any securities exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_31"></A>DESCRIPTION OF THE WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of our common stock, preferred stock or depositary shares representing shares of preferred stock.
Warrants may be issued independently or together with any of the other securities offered by this prospectus that are offered by any prospectus supplement and may be attached to or separate from the securities offered by this prospectus. Each series
of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent specified in the applicable prospectus supplement. The warrant agent will act solely as our agent in connection with the warrants of such
series and will not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the following terms, where applicable, of the warrants in respect of which this prospectus
is being delivered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies in which the price or prices of such warrants may be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, number and terms of the securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the other securities offered by this prospectus with which the warrants are issued,
and the number of the warrants issued with each security offered by this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related securities will be separately transferable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which and currency or currencies in which the securities purchasable upon exercise of the
warrants may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants shall commence and the date on which that right shall
expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the minimum or maximum amount of the warrants which may be exercised at any one time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material U.S. federal income tax considerations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the warrants, including terms, procedures and limitations relating to the exchange
and exercise of the warrants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_32"></A>DESCRIPTION OF THE RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue rights to our shareholders for the purchase of our common stock, preferred stock or depositary shares. Each series of rights will
be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent, all as set forth in the prospectus supplement relating to the particular issue of rights. The rights agent will act solely as our
agent in connection with the certificates relating to the rights of such series and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights. The rights agreement
and the rights certificates relating to each series of rights will be filed with the SEC and incorporated by reference as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the terms of the rights to be issued, including the following, where applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date for determining the securityholders entitled to the rights distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of shares of common stock, preferred stock or depositary shares purchasable upon exercise of
such rights and the exercise price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of rights being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which such rights may be transferable separately; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise such rights shall commence and the date on which such right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any special U.S. federal income tax consequences; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such rights, including terms, procedures and limitations relating to the distribution,
exchange and exercise of such rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_33"></A>DESCRIPTION OF THE STOCK PURCHASE CONTRACTS AND STOCK PURCHASE
UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue stock purchase contracts, including contracts obligating you to purchase from us, and us to sell to you, a
specified number of shares of our preferred or common stock at a future date or dates. The price per share of stock and the number of shares of stock may be fixed at the time the stock purchase contracts are issued or may be determined by reference
to a specific formula described in the stock purchase contracts. We may issue stock purchase contracts separately or as part of units, known as stock purchase units, consisting of a stock purchase contract and beneficial interests in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior debt securities or subordinated debt securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt obligations of third parties, including U.S. Treasury securities, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which may or may not secure your obligations to purchase the stock under the stock purchase contract. The stock purchase contracts may require us to make
periodic payments to you or vice versa, and these payments may be unsecured or prefunded on some basis. The stock purchase contracts may require you to secure your obligations in a specified manner. The applicable prospectus supplement will describe
the terms of the stock purchase contracts or stock purchase units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_34"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise set forth in a prospectus supplement accompanying this prospectus, we may sell the securities offered pursuant to this
prospectus to or through one or more underwriters or dealers, or we may sell the securities to investors directly or through agents. Any such underwriter, dealer or agent involved in the offer and sale of the securities will be named in the
applicable prospectus supplement. We may sell securities directly to investors on our own behalf in those jurisdictions where we are authorized to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters may offer and sell the securities at a fixed price or prices which may be changed, at market prices prevailing at the time of
sale, at prices related to such prevailing market prices or at negotiated prices. We also may, from time to time, authorize dealers or agents to offer and sell the securities upon such terms and conditions as may be set forth in the applicable
prospectus supplement. In connection with the sale of any of the securities, underwriters may receive compensation from us in the form of underwriting discounts or commissions and may also receive commissions from purchasers of the securities for
whom they may act as agent. Underwriters may sell the securities to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom
they may act as agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our common stock may also be sold in one or more of the following transactions: (i)&nbsp;block
transactions (which may involve crosses) in which a broker-dealer may sell all or a portion of such shares as agent, but may position and resell all or a portion of the block as principal to facilitate the transaction; (ii)&nbsp;purchases by any
such broker-dealer as principal, and resale by such broker-dealer for its own account pursuant to a prospectus supplement; (iii)&nbsp;a special offering, an exchange distribution or a secondary distribution in accordance with applicable New York
Stock Exchange or other stock exchange, quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market rules; (iv)&nbsp;ordinary brokerage transactions and transactions in which any such
broker-dealer solicits purchasers; (v)&nbsp;sales &#8220;at the market&#8221; to or through a market maker or into an existing trading market, on an exchange or otherwise, for such shares; and (vi)&nbsp;sales in other ways not involving market
makers or established trading markets, including direct sales to purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriting compensation paid by us to underwriters or
agents in connection with the offering of the securities, and any discounts or concessions or commissions allowed by underwriters to participating dealers, will be set forth in the applicable prospectus supplement. Dealers and agents participating
in the distribution of the securities may be deemed to be underwriters, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled, under agreements entered into with us, to indemnification against and contribution toward
certain civil liabilities, including liabilities under the Securities Act. Unless otherwise set forth in an accompanying prospectus supplement, the obligations of any underwriters to purchase any of the securities will be subject to certain
conditions precedent, and the underwriters will be obligated to purchase all of such securities, if any are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters,
dealers and agents may engage in transactions with, or perform services for, us and our affiliates in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
indicated in the prospectus supplement, we may authorize underwriters or other agents to solicit offers by institutions to purchase securities from us pursuant to contracts providing for payment and delivery on a future date. Institutions with which
we may make these delayed delivery contracts include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others. The obligations of any purchaser under any such delayed
delivery contract will be subject to the condition that the purchase of the securities shall not at the time of delivery be prohibited under the laws of the jurisdiction to which the purchaser is subject. The underwriters and other agents will not
have any responsibility with regard to the validity or performance of these delayed delivery contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of the securities hereby, certain underwriters, and selling
group members and their respective affiliates may engage in transactions that stabilize, maintain or otherwise affect the market price of the applicable securities. Such transactions may include stabilization transactions effected in accordance with
Rule 104 of Regulation M promulgated by the SEC pursuant to which such persons may bid for or purchase securities for the purpose of stabilizing their market price. The underwriters in an offering of securities may also create a &#8220;short
position&#8221; for their account by selling more securities in connection with the offering than they are committed to purchase from us. In such case, the underwriters could cover all or a portion of such short position by either purchasing
securities in the open market following completion of the offering of such securities or by exercising any overallotment option granted to them by us. In addition, the managing underwriter may impose &#8220;penalty bids&#8221; under contractual
arrangements with other underwriters, which means that they can reclaim from an underwriter (or any selling group member participating in the offering) for the account of the other underwriters, the selling concession with respect to securities that
are distributed in the offering but subsequently purchased for the account of the underwriters in the open market. Any of the transactions described in this paragraph or comparable transactions that are described in any accompanying prospectus
supplement may result in the maintenance of the price of the securities at a level above that which might otherwise prevail in the open market. None of the transactions described in this paragraph or in an accompanying prospectus supplement are
required to be undertaken by any underwriters and, if they are undertaken, may be discontinued at any time without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell
the securities in exchange, in whole or part, for consideration other than cash. This consideration may consist of services or products, whether tangible or intangible, and include services or products we may use in our business; outstanding debt or
equity securities of our Company or one or more of our subsidiaries; debt or equity securities or assets of other companies, including in connection with investments, joint ventures or other strategic transactions, or acquisitions; release of claims
or settlement of disputes; and satisfaction of obligations, including obligations to make payments to distributors or other suppliers and payment of interest on outstanding obligations. We may sell the securities as part of a transaction in which
outstanding debt or equity securities of our Company or one or more of our subsidiaries are surrendered, converted, exercised, canceled or transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares are listed on the New York Stock Exchange under the symbol &#8220;ELV.&#8221; Any securities that we issue, other than
common shares, will be new issues of securities with no established trading market and may or may not be listed on a national securities exchange, quotation system or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market. Any underwriters or agents to or through which securities are sold by us may make a market in such securities, but such underwriters or agents
will not be obligated to do so and any of them may discontinue any market making at any time without notice. No assurance can be given as to the liquidity of or trading market for any securities sold by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_35"></A>VALIDITY OF THE SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with particular offerings of the securities in the future, and if stated in the applicable prospectus supplements, the validity
of those securities may be passed upon for the Company by Hogan Lovells US LLP and Faegre Drinker Biddle&nbsp;&amp; Reath LLP and for any underwriters or agents by counsel named in the applicable prospectus supplement. With respect to certain legal
matters relating to Indiana law, Hogan Lovells US LLP has relied upon the opinion of Faegre Drinker Biddle&nbsp;&amp; Reath LLP, counsel for the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom11296_36"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and financial statement schedule for the year ended December&nbsp;31, 2022 of Elevance Health appearing
in Elevance Health&#8217;s Exhibit 99.1 to the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2023, and the effectiveness of Elevance Health&#8217;s internal control over financial
reporting as of December&nbsp;31, 2022 have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated
financial statements and financial statement schedule are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g11296g00r30.jpg" ALT="LOGO" STYLE="width:2.44079in;height:1.05292in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Elevance Health, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195;% Notes due 2028 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195;% Notes due 2032 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195;% Notes due 2036 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>$&#8195;&#8195;&#8195;% Notes due 2055 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>BofA
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Deutsche Bank Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Mizuho </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g11296g00r01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g11296g00r01.jpg
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"\CC3% MS'45
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2HY54<&KO=/\-E]#$R*XQAM(0;;-51$6$M"(B (B( B(@"(B (B( B(@"(B
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M?!)?H%0FKLQ+W.W7P27Z!4)J6'PSRP(B^M-!+55,5/31NEGE<&,8T9ESB<@
MMA6?)%3NCS0I:;71Q56*(FW"Y. <87'\3%S9#V1Y2=G-QK2H\-6*.'J4=EMK
M8MVH*5@'DR6665%/26R:K9#"*M,::'L-W^ED=;Z:.TW#+-DM,W583R.8-F71
MD5+F(;-6X?O-5;+G%U.JIW:KAQ'D(/&",B.E6U71LX/'%HZY:EP?L7/L.+F6
MNHD/W/NA$1:3L9+[1WC]CXQR++5^X97P31RQ.+)&.#FN&\$;05.<5.+BSQ/3
MV7TBZ_#EQ%WL%MN+<LJNFCFR'%K-!R\Z[!<=K1H/,:1<7TN#,.2W&I DJ'?B
MZ:#/(RR'<.@;R>3Q*.;_ 'BNOUVJ+E=9W3U4[LW..X<@ X@.(+V&FS%CL48T
MJ&PR:UNH"::G .PY'MG^,CR +/UT\>KHCM\LHE+;"(!F<AM*W'1KH0?<*:&Y
M8N?+3PO ='11G5D<.(O/M>@;><*R=D8+<CQ)O@PY%;=JP/ABU1-916*WMR]L
M^$2/^4[,^=<BMPGAZM865=CMDH/NJ5F?ERS6?S:^"?ALAQ%3N,M!=DN4,DV'
M7NM=9O$9<7PN/(0<RWI!\2R/#&BV^7'&QL5SII*..GRDJI\LVB+/86G<2[+(
M>/D*MC?"2WLBXM'=Z \ RWV\1WZO#X[90R!T61+3-*-H /N1L)\G*JA7%M-N
MI;3;:>@M\+8:6G8(XV-W #^_.N1-(R&)\LK@R-C2YSB<@ -Y6"VQV2V6Q6D>
M TR8];@RQ!E&YKKQ6 MIVG;U,<<A'-Q<IZ"I(JJB:JJ9:BIE?+/*XO?(\YN<
MX[R2N_TB8FEQ9BRNNDA=U%SNIT[#[2)OL1_<\Y*\VM]%7AQ_95*6V%^F,=(]
MK(VESW'(- S)*[+#%BK<27NEM=LCUZF=V0)]BP<;B>( ;57.C_1[9L&T3!20
M-GN!;^-K9&@O<>/5]RWF'CS2VY5_8C'J)6IL"8JJ8A+#AZZ.8=H)IG#/RA=3
M=;/<K1(([K;ZNC>=PJ(7,SZ,QM5WKCW"AI;C224MPIH:FFD&3HY6!S3XBLZR
MWONB?AD%(M8TUZ,FX4E%VLK7NLTS]5T9.9IWG<,^-IXB>@\2R=;(34UM%;6C
M6-!>D23#ETCLUUF)LU4_58YQV4TAW.'(TG?Y>7.I5 2KK07BAV)<#PMJI->N
MM[NM9B3M< .T<>ENSI!63*JU_-%E<O8T-$18BP@)$1=HS!%ZC1SA"7&M_?:X
M:ME(YL#I^J/87C80,L@1[I:;^#Q6_K#3?-G?:5<K80>I,]46^#"D6Z_@\5OZ
MPTWS9WVD_!XK?UAIOFSOM*/F*_D]Z&84N?A[\_6WPF+Z86S?@\5OZPTWS9WV
MER+;H K*2X4M2;_3N$,K9"T4[AGD<\O9(\BO7(Z&4 B(N67F?:?>]9>.F'UK
M%(:KS3[WK+QTP^M8I#71Q/0_LIGR%5'!J[W3_#9?0Q2NJHX-7>Z?X;+Z&+W*
M] KY-5408\N[K]C&\7(NUFSU#NIG]@'58/D@*T,0U!I+!<ZEIR=#32R ]#2?
M[*$55AKEGM@7M=#N'&8FQ[;Z2H8'TD.=3.TC,%C.(\Q<6CQKQ2^D$\M.XN@E
MDB<1D2QQ:<O$MDDVFD5HOE%!OW2KOTVI_FN^M/NE7?IM3_-=]:Q^3?R6^(7D
MB@W[I5WZ;4_S7?6GW2KOTVI_FN^M/)OY'B&B\(?#[+-CMU73L#:>YQ]<9 ;!
M)F0_RD!W\2R]?6>IGJ-7J\TDNKNUW%V7E7R6N$7&*3*V]LY=IKI;9=*.NISE
M-33,F9TM((]"NVDG954L-1$<XY6![3R@C,*!U;NCV5TV \.R/VN-O@S/*>IM
M67+79,G6>9T^6#[MZ/:N6)FM4VYPJV9#;JC,/'R23X@I(5]5$,=1!)#,T/BD
M:6/:=Q!&1"AS%UFDP_B:YVJ7/.EG<QI/MF[VGQM(/C3$GV<18O<ZA47P7;YU
M:UW6R2N[:GD%3$#[EVQV7,"!\I3HO<Z%+Y]PM(EKE>[5@JG=:2]#]@\CM4^)
M7W1ZH-$8O3+$1%P,07.*S6.ON51EU.D@?,1RZH)R\>Y<I+9>2WP@;[]U](53
M3QOUJ>W,;2MRW:PVO\>L2/X5FJ^U;52UM94550[7FGD=*]W*YQS)\I7Q78A'
MIBD9V]L]+HWL)Q)C6U6TMUH7S!\WQ;>V=Y0,O&K8    &0'$L X+E@VW:_S,
MW94<!/B<\_0\ZW]8,J?5/7P6UK2,#X4UU<(K':&.[5Q?52#H[5OI>I^6L\)B
M<RZ0H8R=D-#&T#I<\_W63+90M5HKER%5F@#"$=@PE%=*B,?=*YM$KG$;61;V
M-'2.V/2.12Y;:8UEQI:4'(S2LC\I _NKQ@B9!!'#$T-CC:&-:.( 9 *G+GI*
M/R2K7N?M$18"T+H,=89I<689K+55M:'2-UH9"-L4@]BX>/?S$A=^B]3:>T""
M*RFEHZN>EJ6%D\#W1R-/M7 Y$>4+XKW>G&A90:3[TV,9,E<R<=+V N\Y*\(N
MQ%]44S,UH[K _=G8?#X/6-5QJ',#]V=A\/@]8U7&L67RBVLZ[$O<[=?!)?H%
M0FKLQ+W.W7P27Z!4)J6'PSRP+5^#=98[ECF2MG8',MT!E9F,_P 8XAK?,7'I
M 64+>>"FT==8E=QAE.//)]2OO>JV1AR4(B(N47A8%PI+)&&6>^1L E+G4DKA
M[89%S/)D_P JWU9)PFP#H_I3EM%PC^A(KJ'JQ$9<$NHB+J%!9.A>9T^C##[W
M;Q"YGB:]S1Z%V.D>\.L.![U<8W:LL5.YL1Y'N[5I\K@NIT'=ZRP_ D]:]=+P
MDJDP:.#&TY">LBC/.!K._P!(7+Z=VZ_9?O\ B2JB(NH4&O<'7!T5\O\ ->;A
M$'T=M+>IM<,P^8[1\D;>DM5/K-^#W0LH]&-!*T /JY99W\YURP>9@6D+EWSZ
MILO@M((B*DD$1$ 7@].-W=9]&UT=&[5EJ@VD8?AG)W^4.7O%BO"DJ"W"]GIP
M>UDK#(?X6$?ZE92MS2(R[(FQ$1=8H*0X,>'&4UCK<03,'5ZMYIX7$;HVGMLN
MEWT0MM4%15M5#&&15,[&#<ULA 'B7[^Z5=^FU/\ -=]:R68SG)RV6*>EHO)%
M!OW2KOTVI_FN^M/NE7?IM3_-=]:CY-_)[XA<.([1!?;%76NK ,-5$Z,YCV).
MYW2#D?$H9K::2BK:BEG;JS02.B>.1S20?.%]?NE7?IM3_-=]:XKW.>]SGN+G
M..9).9)5]-3JVMD)2V?Q;%P8KJZEQC76YSLHJVE+@.5[#F/,7K'5[S05*Z+2
MG8RWVSI6GG!B>%*U;@SR/)8*(BY)H("1$7:,QK'!G[X<W@$GTF*I5+7!G[X<
MW@$GTF*I5SLKUEU? 1$68F$1$ 1$0&?:?>]9>.F'UK%(:KS3[WK+QTP^M8I#
M71Q/0_LIGR%5'!J[W3_#9?0Q2NJHX-7>Z?X;+Z&+W*] KY-#Q- :G#=V@:,W
M2TDK .EA"A17Z1F,CN4-8PM+K'BFZVQ[2WK:H>QO.W/M3XQD55AOE'MATZ[S
M"6%;KBRMFI+' R>HBCZJYKI6L[7,#/MB.,CRKHUZ_1/B5N%<;T%?.[5I'DP5
M!Y(W;"?$<G>):YMJ+<>2M?L[?L+8W][(?G47VD["V-_>R'YU%]I5LQS7L:YC
M@YKAF"#F"%_5A\W/]%WAHDCL+8W][(?G47VD["V-_>R'YU%]I5NB>;G^AX:)
M(["V-_>R'YU%]I.PMC?WLA^=1?:5;HGFY_H>&B2.PMC?WLA^=1?:50X0M\MJ
MPK9K?4 ">EHXH9 #GDYK #MZ<UVR*JRZ5BTSV,5$*;^$]8.MKY;KY"S*.KCZ
MA,1_B,W$]+3E_"J07B=,M@^^'1]<X(V:U33MZZAV;=9F9('.6ZP\:43Z)IB2
MVB.%^HWNC>U['%KVD$$;P5^475*"X\%7EN(<*6JZM(+JF!KGY<3QL</$X$+/
M>$K?/N?@N&V1NREN4P:X?_FSMG>?4\JX/!@OG7.'KC9I79OHYA-&#[A^\#H<
M"?XEG7"'OOW6T@2TL;LX+;&VG&1V:_LGGRG+^%<^NK5VO@M<OXF8H!F<AO1>
MST/6#[X=(%KIGLUJ>!_74^S9J,VY'F)U1XUOD^E-LJ2V5)HTL/WMX(M5M<W5
MG9$))OC'=L[R$Y>)>F1%QV]O;-*[$L<)6$QZ16/.Z6BB</E/']EE*WKA3VPB
MIL=U:WM7,?3/=R$'6;Z7>18*NI0]UHHER<JTU(HKI1U1W03,D^2X'^RO)CVR
M,:]A#FN&8(XPH#5=:#<5QXDP330R2 W"W-;33M)VD 9,?XP/*"J<N.TI$JW[
M&AHB+ 6A$758JOE+ANP5MUKG 0TT9<&YY%[O:M'.3D%ZEOL@2MIWJVU>E"\&
M,@MBZG#F.5L;<_/FO +E72NFN5RJZZJ=K3U,KII#RN<23Z5Q5UX1Z8I&=O;.
MZP/W9V'P^#UC5<:AS _=G8?#X/6-5QK'E\HLK.NQ+W.W7P27Z!4)J[,2]SMU
M\$E^@5":EA\,\L"WK@I_E&)O@4_ID6"K>N"G^48F^!3^F179'XV1AR4&B(N6
M7A9+PF^]]3?O&/Z$BUI9+PF^]]3?O&/Z$BMI_(B,N"7$1%U2@L30=WK+#\"3
MUKUT7"6@,NCMCP-D-;$\]!:]O]PN]T'=ZRP_ D]:]<W2O:'7O1[?*.-NM+U
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MYO\ ^T[.>#O\2O\ F_\ [4IHH>5@>^(RK.SG@[_$K_F__M.SG@[_ !*_YO\
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M!]-([)LAY8R=_1O'G4BHEM,;%W$9.)?J*)+5C?$UJC;'07VX11-V"/JQ<T=
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M7_O!_JXULR8I0[%<.37T1%SBX*.L8XPQ)3XMOD,%_NL<,==.QC&5<@:UHD<
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MDT9$1<XN"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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>*XN;'(QH:[-I;MRZ5T)9$'%K92H/9JB(BYY<?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g11296g00r30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g11296g00r30.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $\ MP# 2(
M A$! Q$!_\0 '  !  (# 0$!              <(! 4& P(!_\0 5!   0,"
M @,'# X(!@$% 0    $" P0%!A$'$B$(,4%187&!$Q07(C=5=)&4L;+2%3(S
M-39"4G)SDZ&SPM$6&",T=8*2P21#5%9BHE,E8V7A\&3_Q  : 0$  P$! 0
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M4N
M
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M1'OY(R  5BX
M
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M/,O*8FHT[I?\/I-)JXZB/]1[@ K%L
M
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MDD;7HBHCD1<G)DO2A] &"?3@
M
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ME
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M#  *9*
M                                                         4%
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MIY8XV\;W(B?: >@,%EXMCW:K+C1N=Q).U5\YFM<U[45JHY%X47,8!^@
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MIQ):XN*[@^)_<)/FKYC[/B?W"3YJ^8KDA0@ &T4C>X!^'6'/XE3?>M+NE(L
M_#K#G\2IOO6EW2CJ^46*>&<AI<NCK1HZOE2QVK(Z#J#%3?SD5&9IS:V?04T+
M2;I6=8M'D<:+[M71L7F1KW?V0JV2Z18ADXM?<'8Z(J"AKL>VWV6J*>"BIG+4
MR.GD1C5U-K4S79M=J[.+,XX%B2RL$:[,O'^D]@[^6ORN/\Q^D]@[^6ORN/\
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MO#XW:LM0QM,W^=V3O^NL=R0]NGIU9@FWPHN225[57ERC?^9)4LS2.9/$65F
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M[_0AB=F&<<4[JIZ,HJUO6LSE78W-4U7+S.1-O$JG=T=T&D>0>)%NP 91:
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MY/5;EXP7)/B?W"3YJ^8^SXG]PD^:OF*1,4( !M%(WN ?AUAS^)4WWK2[I2+
M/PZPY_$J;[UI=THZOE%BGAGX]C7L<QZ(YKDR5%WE0I3I$PY)A;%]QMCFJD+)
M%? Y?C1.VM7Q;.=%+KD8:=<"NQ386W"W1:UVH&JK6M3;-'ON9SIOITIPD>GL
MV2P^&>V1RBJ@"HJ*J*F2H#2*Q8;0=I1@DHZ?#N(ZA(IXD2.DJ9%R;(W@C<O
MJ;R+PILW]^="@IW>$=*N*,-1,IX*MM91LV-@K$5Z-3B1V:.3FSRY"I;IMSS
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MMF'M?V16QRLD(@ T"N6+T-:6:>II(+'BBH;#5QHD=/62KDV5-Y&O7@=RKO\
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MGE3?9*Q6.3H4NQG&7#(&FN3P ")GO'1X ='8<#XEOSFI;+-62,=O2O9U./\
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M>VGABC6-[&M1&MRR1%5-XFK5;EW.).6"Q@ *I*
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M P85%:;=0KG16^DIUXX86L\R&: >
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M9_-./N_OK6_3O])3RHOWR#Z1OG-?IPQP5-S]E] $!D%L
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MHTEXE@Q;BZJN]+!+!%,R-J1R*BN35:B<',<N:E::@DRK+NV7#T)=RZP_1O\
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M/7)D<SD=&]>)K]FWD5$Z3V5$XK+1XK(LDP $)V
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M[.=%Y%)B*5Z-+L^R8[LE:UVJQ*EL<GS'KJN^Q5+J&?J8*$LK[)ZY90 !7)
M
M    "F&E?NCXB\+><H=7I7[H^(O"WG*&Q#Q14?+,J.W5LK&OCHZE[')FCFQ.
M5%3Q'U[%7#_05?U+OR+BZ+.YUAWP*/S'4E5ZMIXP2*K/V41]BKA_H*OZEWY#
MV*N'^@J_J7?D7N!Y\Q^CWH_TH3/!+3R:D\3XGY9ZKVJU?$IYDH;H_ND/\$B_
M$1>6X2W13(FL/!:O<X]S:/PJ7SH?FZ,N3J'1V^GC=DZNJ8X%R^2F;U]!/&?N
MYQ[FT?A4OG0TVZC1WZ+V=4]JE8J+SZCLO[E!+-__ -)__0K:=GHDO-EP_B^*
MZX@ZJL--&YT*1QZZ]57)$54Y$5R\^1QAD45!5U[W-H:6HJ7-3-R0QJ]43ER0
MT))-8973PRT79RP?\NO\G_\ L=G+!_RZ_P G_P#LK3^CMZ[SW'R5_P"0_1V]
M=Y[CY*_\BM\:OV2=219;LY8/^77^3_\ V5KQ9-;ZC$MRGLNLENEG=) CFZJM
M:Y<\LN#+/+H/G]';UWGN/DK_ ,A^CMZ[SW'R5_Y$E=<*WF+.92<N35EV-'5P
M==,"V*LD76DDI(T>O&Y$U57QHI3O]';UWGN/DK_R+;Z(J::CT<6*"JB?%,V%
M=9CVJUS<WN7:B\Y%J\.*.ZN2O6Z!N#J[277QJ[-E'%%3LY$U=9?M>I')V&F!
M')I+Q!K;_7'V:J9''EBM8@B.7++3;G?#45IP6RZ21IU[<U617*FUL2*J-;S;
M%=TIQ$J'-Z-71OT?X<6'+4ZPA39QHQ$7[<SI#+L;E)MEF*P@:?%]AIL2X=KK
M56-165$:HURI[1_Q7)S+DIN <IX>4=%":J"2FJ98)FZLL3U8]O$J+DJ?8>9O
M,=OC?C;$#H<NIK7SJW+BZHXT9L)Y62FR\N$?@K9? H?00X[=!]R^X_2P_>-.
MQPC\%;+X%#Z"'';H/N7W'Z6'[QIEU_L7^EJ7B5+)6W-7=$D\!E])A%)*VYJ[
MHDG@,OI,-&[];*\/)%I  9):*C:?.ZG>/FP_=,(^)!T^=U.\?-A^Z81\:]7@
MO\*DN67!T'=RRP_,E^]>=R<-H.[EEA^9+]Z\[DR[/-_Z6H\(  X/2B%W]]:W
MZ=_I*8L;%>]K&[[E1$,J[^^M;]._TE/*B_?(/I&^<VEP4R]5JHHK;;*2AIFH
MV&FB;"Q$XFIDGF,H(#%+AXUE-%64<]+4,1\$S'1O:O"U4R5/$I1&M@6FK)Z=
M5S6*1S%7CR54_L7T*)WWW\N/A,GI*7=']D-OT8E.Y63QO:N3FN147I+[-7-J
M+QH4(B]T;SH7WC]HWF0:SZ%/V?H *1,
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MZ-YT+[Q^T;S(4(B]T;SH7WC]HWF0]UGT*?L_0 4B8
M                                               IAI7[H^(O"WG*
M%P;QHJPE=[I4W"OM\DE54O621R5$C<W+R(N2&)V&,$]ZY?*I?6-".IBDD5W6
M\F[T6=SK#O@4?F.I,2T6ZFM-LIK?0L6.EIHTCC:KE=DU-Y,UVJ990D\MLG7
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B,X)145+7+FG_ /5+ZQ(B)DB(F\>ZBU68P*XN/( !6)#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g11296g60s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g11296g60s01.jpg
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M=8>SN#I#1)37_\0 ' $!  (# 0$!              8'! 4( P(!_\0 5!$
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MAY.SKBR5WDDAMY))&9Y)'OHF=W8EF=V9B69B268DDDDDYJ=+Q#I2J%5I%50
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MZU-;;0-+NH(KB.2Z*2H&'UV/H3[Y3]9\U;*D>A!KNG][)>/C_OYVG_M%UO\
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M)=0UAT9(&@%A;LP($S-*DT[)[5B,,2EAT+.R@Y1P(AQ3<H4M[12"X<SR ?<
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M%^  +V[    %S,  .@  ?  'D*]K]T/[^?RW^W7^\?N'_&//SZF^'OY"T?\
MLVS_ '-?ONCJ'\>O/TF?]NK3WPTO8??N^V>Z&=Y;OVYN7-5<Z[XJ^=J;'N&P
M<US$XG>69K$%FV3$MF)Q+YB(G[3P!]/]?]F1_P!5\WZ,?Y=3]I^FZ?IYT3N%
MA9V7.&I<WNEM#;\W9W#9S.2B;]F]]F[.W>V,;CF5<,W-Q<=]Y\\TVSNVSFRO
M)MW=XW;=[-C=M7.,9P,^50A?$$?K3-[?S8TO_=!2^3OL[^*>G_A;[]=GK1\0
M?"MQ_-@^@CJS_P##I?JS:5_2MMO]HF^57VD_&B?\4L_HJE'#?P8GX:;_ !%1
M;>=[P_WTW8%K[N]7:>?<(:W97.;]UG6 '3K'!65IG&)':-:A@VUE3<'8&VDG
M7@$!A^5AYW!UK6T=#R\N]6Y7P#QG;K;0Z%JLRP/#X-/NI6"Q219RMK*[=(WC
MSM@9B$>/;#E71!+J]>T>0R/?6J;U?Q7$2CQ*_K*BCWRMYR >(-E\$,Q2 ?J)
MY&>W_1I^3%Z^[5.K]8F3?KY_7EBC8ZV4*4D<-MLN2"ZU.CE,Q$N\TP.P7-5U
MV%FBQQ!1"Y!X0=MA-A:SPUHVO!#J-HLDJ+MCN8W:&X1<DA>;&070$DK'*)(U
M+,RJ"2:C]GJ-Y8D]WF*HQRT; /&QQC.Q@0&P!EEVL0 "2!BLF.P'G.\C/86H
MR%#F-NQFMZM,B.@SH6G:P%1I.9#?1EI\0FUI>D[@&*2TIQDP6&L$6*<.ZZ,<
MR2.O+7-9IW ?#6G3+<)9-<RH0T;7LK7"(P.0PA(6%F!P59XW*D J0>M95QKN
MI7"&,S")&!#"%!&6!]"_5P/:%8 @X.:GI^&?V!VUD=3["UW?*//%=3X)3T[I
MW9MD<?CT1ERD)9.+/0J2P>W\^TU216\?9##(I6(FH6064&???/M>1PZ_[4+?
M1UN[:YMYXQJ\F([VUB ;= J?6KB<J<0RIA8E5_'-$R$ +#EM]PS)=F&2.2-C
M:+XH96.,.3XHT!ZNAZL2/"C @DE\"TIRJ*E54)_B1^L7X(>Z<'O:%C_IJIV;
MI8\T:\TU\L9.RM>,QM4N [:$8^4C)5><HD\^[ZI<,E)F6?6A2\./.] ]F>J]
M\T.33W;,VESE "<GNMR6FA/MZ2"XC \E5$ /4 0'B6UY-ZMPHPET@8GTYL8"
M./RKRV/M+$^>:K['3,Y.-P@,C(R,JW!1J8"OBE$/EXBXE4G(2R(B,:<4O(X6
M968DSFPV,):P7(%.H1A;Z\YL14CC,C*JIS&YDI "[WV*A=R,9;8B*6/7:H&>
ME1\LS;026VC:H/7 R3M'R98G'M)K: ^-[K.CJ+TGZ_Z/)!2#9X.D!S^PD>Q.
M'E;'NKKMMN[+[OIA9.(J>F"X(%YWT7B*BH]C"6FV6VF^5^)M4]V-<U&_5MT,
MD[1VQ].[0 0P$#TWQH)& ^[=CUSFK0TRU[G8V\!&'5 TGX5SOD!/KM9BH^0
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M)O\ JX;+_:G7'(1VG_%N/^D[7Z&ZK=<,_"+?BTO^>*LM_BI?])/3C^8^X?\
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M,F['K>6J4U-&*SGTR7*G&$^W"4?-]B4IQO[#BGB#3(UBLM5NHXE&$AD*7,2
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M3@6(3\%Z?"Q*K-'J<1(QD"2_O4)&>F0#D9Z9J/ZVYCUJX< $H]LX!\B5MX"
M?DZ5V)N*U>?S;U*D>X]AD^W5.U05'.7D)6K+G-ZNJ]=IRFLR0LS$ZFI5HB+.
MU4P(?*#&[3*UF0<(@F_MN6GSV'")-[&LH>SVSG318TT>>\5N[MWJ!+N62?.Q
MD>[GBDB,S/E>4LJA7/+2-3A!ZS-Q!-&;QC=I"1S!R7,2JA\0*Q1NK[ N"'92
M2OB+'S,NW@3\LVXNS-SL74KL[9EWRZQU0-NNJ-G23(H]FG(ZOD!CV2E6Q\)D
M=N?DQ #F9^"GGQDRKX$;86IZ0DGTQCB(=V@<(66EP1:QI47=X'F6"[M5),4;
M2 F*>$,28U9E,<D8)0,T9C51O%;?0-6FNG:TNFYCA#)#*0 S!2 T;D>^(!W*
MV,X#[B3MJTIRJ:E5.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE1 ^>
MK]4]VL_]#/\ Y):>Y,NS_P"-VD?\_P#],O:T^O\ P3=_\#]9AJK_ .&3Q/Z(
M\CM*WI9=P7W;=.,U=::9!PC&M9*G "G"V.)FSS'95-HIEJ=<?9=C&$#9$=#;
M2VMW#K;JLH4BU.-N+M0X:GL(K*WLYENX9Y)#=).Q4Q.BJ$Y4\( (8YW!CG&"
M*B^BZ3;ZDEPTTDR&)T5>4R $,&)SOC?KTZ8Q4NNR?AG>F--UU?K?';J[/$R%
M4I5IL@ YM@U4L-\R"@SY05DM#&IAWU"NOBH00EE]EU32EX;=;7G"TPZV[4-;
MFN;>%K'2@LT\43%8[O<%DD5"5S>$9 )QD$9\P:V\O#-C'%(XFNB4C=P"\."5
M4D XA!QD=:B=^&E_6*3?]7#9?[4ZXY+NT_XMQ_TG:_0W5:GAGX1;\6E_SQ5A
MAO!_>,]Y@=NN:^#A)3?RN]]\8UG&W==>3 /W>)W'*BZXC"_OD2+678]I\*!"
MA6)HE,84TW',*4\TZA+F[L!81\&68N3(NG^X%N;IH!)S! ]DAN67D R[B&D9
MR@W@ECYY-84YG;6)C&%-QW^01"3;MWB8B('?A<=%"[L ]*L,_;GQ2/\ W.U)
M_P#M=4?\4\KG9V4_[:\_-J_[JI%NXI^\A_/:?M5AUT3\2_DYU#Y"]+]H-H:7
MK5,KT=N*4NNQIFO;*T]D"*A+@W/#7!F)JU6N193<:0!/R,<+"PT<ZVP$0D1A
MC [?HG<Z_P 7\+7G#E[I-I>RSR-9)!;)+:WFYW@,9@+RRPJ"X:-6+NPRPW$Y
MK"L-(U2'48+J6!$43%Y"LL. K[@^U$<G&&("J.@Z8Q6$'=D6!N?G@M<-O=32
MZ%+]S-,5F\XFE80!G56)?74#AH];V<(:AU:^;&;==5ZMMQF<NI2I.,)SOM":
M2#@"%[#/>$T6^EM^7G<+O9<R97'4N+@DX'4MT'MK!O@KZ\XG^QF]@63=Y<K,
M2G.?N3'^3'R5L06661V6AQVFV&&&T,L,,H2TRRRTG"&VFFT82AMMM"4H0A"<
M)0G&$IQC&,8YSB2222223DD]22?,D^I-6+Y>5:XSS?P.OJ[Y4NP(FNVH\80V
M7UQ.6L.*2RD >_SU#J<O<%HPQZM_72,J8Y,3OYRG<6*1EL$>PG#K2.E.!9+F
M3A+3FN2Q*I=)"SYW&WCN)DASGKM5%V1^G*5".A%5OKBQKJMP(\ %HV8#  D:
M-"_EZDG+?[Q.>M3T_%+?ZM_6+^FZP_L&?R =E'PEJOXC%^L+6_XJ^UK7\.WT
M9K/WP#?JJ.MO_F>[O[^ME\CO:%\;=4_FV'_3K2MAP_\ !-K\\_ZQ+55[M3_]
M0"5_7TT/^VFM>6QI/_AV/_Q_4/H+JHI=?& _TA!])'6PRYSG5B5KSO,?&@S/
MFWVK#R@K1T9*W_JQ&R(1"<+8+ .TQI$4P5Y&?R+9('=<:<3G\BD+5C/Z>=&<
M%NT? MJZ$JZ6^K.K#S5EO;XJ1\H(!%5YK"AM<E5AE6EM%(]H,$ (_*#6PJ6,
M,X,H-8["Q%L*&6*MIM0RQE-Y:4.IC*<M*84UG+:FLIRWEO.493[?R<YTR0<@
MG.<YSUSYYSYYSUS5AX&,8Z>6/3'LK7N^$H(:#\S&N(:*;P%& S796)%$9]4M
M-1P&KMH($$PG_M:82*/[$Y_)C+*,_I3CG17'+&3@FYD<[G:/2W+'S+-=VA8_
M.<G\]5YH8 UF,#H ;D #RP(I0!\U;"GG.E6'3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI43_G#JMGNOBZ[/UBFUR>MMDD_P "OV;7JS#R$].2'T78
M?4L@9]#$Q0Y9Y?T@ A1Q/R!W/D!C$$N^QEEQ:9=P)+%!Q7I4LTD<,2]^W22N
ML<:[M-O%7<[D*,L0HR1EB .I%:G7$>32[I$5G8\C"HI9CBYA)PH!)P 2<#H
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MO;2N$-U:3-(RM$"1S (Y3#(J$NA0,P59$)C6O65Q;WS7L2.8I&CE65%W"*5
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45>L<N/$5 Z^G7KZ5?,YS_4]K_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
